BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Myoid hamartoma of breast with chondroid metaplasia: a case report.

Breast hamartoma is an uncommon poorly recognised benign breast neoplasm.

Hamartoma displaying marked smooth muscle components known as myoid hamartoma of the breast is a much rarer entity.

We present a case of myoid hamartoma of breast with chondroid differentiation in a 46-year-old woman.

The painless breast lump was circumscribed and mammography showed a well-encapsulated large, dense mass with no calcification.

The various immuno-histochemical staining as well as the cyto-histological changes encountered in myoid hamartomas are discussed with clinical, radiological and pathological correlation to differentiate it from other benign and malignant breast lesions.

[MeSH-major] Breast Diseases / pathology. Hamartoma / pathology. Muscle, Smooth / pathology

[MeSH-minor] Biomarkers / metabolism. Breast Neoplasms / diagnosis. Cartilage / pathology. Cell Differentiation. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Humans. Immunohistochemistry. Metaplasia / pathology. Middle Aged

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19694319.001).

[ISSN] 0126-8635

[Journal-full-title] The Malaysian journal of pathology

[ISO-abbreviation] Malays J Pathol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Malaysia

[Chemical-registry-number] 0 / Biomarkers

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

INTRODUCTION: Fibroadenoma is the most common benign tumor of the female breast with the highest incidence before age 30.

CASE PRESENTATION: We present a rare case of a 39 years old female with invasive ductal carcinoma arising within fibroadenoma.

CONCLUSION: There is a low percentage of fibroadenomas harboring carcinoma; however, all breast lumps should be seriously managed; extirpation and histological examination is recommended.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Indian J Cancer. 2009 Jul-Sep;46(3):244-6 [19574682.001]

[Cites] Pathol Int. 1994 Dec;44(12):874-7 [7866572.001]

[Cites] N Engl J Med. 1994 Jul 7;331(1):10-5 [8202095.001]

[Cites] Am J Clin Pathol. 1991 May;95(5):614-22 [1850948.001]

[Cites] Surg Gynecol Obstet. 1985 Feb;160(2):99-104 [2982218.001]

[Cites] Can J Surg. 1985 Jul;28(4):372-4 [2990650.001]

[Cites] Am J Clin Pathol. 2001 May;115(5):736-42 [11345838.001]

[Cites] Major Probl Pathol. 1979;11:i-xvi, 1-466 [547120.001]

[Cites] Cancer. 1975 Feb;35(2):450-6 [1111920.001]

[Cites] Int J Clin Oncol. 2004 Aug;9(4):334-8 [15375712.001]

[Cites] Gynecol Oncol. 2004 Aug;94(2):572-4 [15297206.001]

[Cites] J Clin Pathol. 2002 Oct;55(10):795-7 [12354814.001]

[Cites] Arch Pathol Lab Med. 1984 Jul;108(7):590-4 [6329129.001]

(PMID = 19946485.001).

[ISSN] 1757-1626

[Journal-full-title] Cases journal

[ISO-abbreviation] Cases J

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC2783130

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Expression of PAK4 in breast cancer and benign breast pathological changes].

OBJECTIVE: To study the role of p21-activated kinase-4 (PAK4) in the occurrence, progression and metastasis of breast cancer.

METHOD: PAK4 expression was detected in 35 cases of normal breast, 22 breast cystic hyperplasia, 28 breast adenofibroma, 37 breast cancer (including 7 non-invasive cancer, 9 early invasive cancer and 21 invasive cancer) and 13 metastatic breast cancer tissues using immunohistochemistry for a comparison of PAK4 expression and distribution.

RESULTS: PAK4 was expressed mainly in the cytoplasm of the cancer cells, occasionally in the cell nuclei, and virtually not expressed in the matrix surrounding the breast cells.

PAK4 positivity rates increased in the order of normal breast tissues, benign changes (including breast cystic hyperplasea and breast adenoma), breast cancer and metastatic cancer tissues; in the cancer tissues, the positivity rates increased in the order of non-invasive breast tumor, early invasive tumor and invasive tumor tissues.

CONCLUSION: PAK4 is closely correlated to the progression and metastasis of breast cancer and may become a new diagnostic and therapeutic target of breast cancer.

[MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. p21-Activated Kinases / metabolism

[MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Young Adult

Genetic Alliance. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20501374.001).

[ISSN] 1673-4254

[Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University

[ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.11 / PAK4 protein, human; EC 2.7.11.1 / p21-Activated Kinases

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: To investigate the clinicopathological and immunohistochemical features, diagnosis and differential diagnosis of nipple adenoma of the breast.

RESULTS: The neoplasms were localized at nipples or under the areola of breast, adherent to the epidermis, mainly composed of dilated ducts in a tubular appearance associated with fibrotic matrix.

The tumor cells were crowding, lack of an uniform morphology and polarity with intact myoepithelial cells around the ducts.

CONCLUSIONS: Nipple adenoma is an infrequent type of benign breast neoplasm, presenting as sclerosing papilloma, papillomatosis or florid sclerosing adenosis.

A correct diagnosis is based on the peculiar location and morphology of the tumor, and immunohistochemistry is helpful in some cases.

[MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology. Nipples / pathology

[MeSH-minor] Adult. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Keratin-5 / metabolism. Keratins / metabolism. Middle Aged

MedlinePlus Health Information. consumer health - Breast Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20079190.001).

[ISSN] 0529-5807

[Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology

[ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] China

[Chemical-registry-number] 0 / CK-34 beta E12; 0 / Keratin-5; 68238-35-7 / Keratins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] ADC mapping of benign and malignant breast tumors.

PURPOSE: The purpose of this study was to investigate the utility of diffusion-weighted imaging (DWI) and the apparent diffusion coefficient (ADC) value in differentiating benign and malignant breast lesions and evaluating the detection accuracy of the cancer extension.

MATERIALS AND METHODS: We used DWI to obtain images of 191 benign and malignant lesions (24 benign, 167 malignant) before surgical excision.

The ADC values of the benign and malignant lesions were compared, as were the values of noninvasive ductal carcinoma (NIDC) and invasive ductal carcinoma (IDC).

RESULTS: The mean ADC value of each type of lesion was as follows: malignant lesions, 1.22+/-0.31 x 10(-3) mm2/s; benign lesions, 1.67+/-0.54 x 10(-3) mm2/s; normal tissues, 2.09+/-0.27 x 10(-3) mm2/s.

The mean ADC value of the malignant lesions was statistically lower than that of the benign lesions and normal breast tissues.

The main causes of false negative and underestimation of cancer spread were susceptibility artifact because of bleeding and tumor structure.

CONCLUSIONS: DWI has the potential in clinical appreciation to detect malignant breast tumors and support the evaluation of tumor extension.

However, the benign proliferative change remains to be studied as it mimics the malignant phenomenon on the ADC map.

[MeSH-major] Algorithms. Artificial Intelligence. Breast Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Artifacts. Female. Humans. Information Storage and Retrieval / methods. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16127252.001).

[ISSN] 1347-3182

[Journal-full-title] Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine

[ISO-abbreviation] Magn Reson Med Sci

[Language] eng

[Publication-type] Controlled Clinical Trial; Journal Article

[Publication-country] Japan

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Nuclear morphometric features in benign breast tissue and risk of subsequent breast cancer.

Certain nuclear morphometric features measured in breast tumor tissue have been shown to predict the prognosis of breast cancer patients.

However, the application of these features to predicting risk of breast cancer development has received little attention.

We conducted a case-control study to evaluate nuclear morphometric features in benign breast tissue in association with subsequent breast cancer risk.

The study was nested within a cohort of 4,888 women with a histopathologic diagnosis of benign breast disease (BBD) and involved 61 cases and 71 controls, amongst whom there were 53 matched case-control sets.

Conditional logistic regression models were fitted to assess various measurements of nuclear size and nuclear shape factors in relation to subsequent breast cancer risk.

In multivariate analysis, subsequent breast cancer risk was positively associated with a nuclear shape factor that takes the shortest nuclear axis and the longest nuclear axis into consideration simultaneously (highest quartile versus lowest 3 quartiles: odds ratio = 3.07, 95% confidence limits = 1.61, 5.84).

In contrast, there was no alteration in subsequent breast cancer risk in association with nuclear size features and other shape factors.

In conclusion, our study results suggest that the shape factor that takes both the shortest nuclear axis and the longest nuclear axis into consideration might be of value to predict subsequent development of breast cancer among women with BBD.

[MeSH-major] Breast / pathology. Breast Neoplasms / epidemiology

[MeSH-minor] Adult. Canada / epidemiology. Case-Control Studies. Cohort Studies. Female. Humans. Middle Aged. Registries. Risk Factors. Surveys and Questionnaires

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Microsc Res Tech. 2002 Oct 15;59(2):109-18 [12373721.001]

[Cites] Int J Cancer. 2001 Sep 20;95(5):282-5 [11494225.001]

[Cites] Histopathology. 2004 Oct;45(4):352-9 [15469473.001]

[Cites] Virchows Arch A Pathol Anat Histol. 1982;396(1):9-18 [7123847.001]

[Cites] J Clin Pathol. 1986 Jun;39(6):603-9 [3722413.001]

[Cites] Lab Invest. 1990 Aug;63(2):270-5 [2381167.001]

[Cites] Anal Cell Pathol. 1989 Feb;1(1):11-23 [2562217.001]

[Cites] Eur J Surg Oncol. 1991 Aug;17(4):350-3 [1874292.001]

[Cites] CMAJ. 1992 Nov 15;147(10):1459-76 [1423087.001]

[Cites] CMAJ. 1992 Nov 15;147(10):1477-88 [1423088.001]

[Cites] Anal Quant Cytol Histol. 1996 Oct;18(5):374-82 [8908309.001]

[Cites] Cancer. 1997 Jun 25;81(3):172-9 [9196016.001]

[Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9 [9731732.001]

[Cites] Br J Cancer. 1998 Sep;78(6):800-5 [9743304.001]

[Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]

[Cites] Urology. 1999 Jan;53(1):44-9 [9886586.001]

[Cites] Dis Colon Rectum. 1999 Mar;42(3):386-92 [10223762.001]

[Cites] Eur Arch Otorhinolaryngol. 1999;256(5):257-61 [10392302.001]

[Cites] J Pathol. 1999 Feb;187(3):272-8 [10398078.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):768-72 [15824141.001]

[Cites] N Engl J Med. 2005 Jul 21;353(3):297-9 [16034016.001]

[Cites] Clin Cancer Res. 1999 Nov;5(11):3542-8 [10589770.001]

[Cites] Pathol Res Pract. 1999;195(11):741-6 [10605693.001]

[Cites] Pol J Pathol. 1999;50(4):235-41 [10721263.001]

[Cites] Int J Cancer. 2000 Nov 20;89(6):494-9 [11102893.001]

[Cites] J Pathol. 2001 Jan;193(1):33-9 [11169513.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):249-59 [11303595.001]

[Cites] Am J Surg Pathol. 2003 Jun;27(6):836-41 [12766590.001]

(PMID = 17061043.001).

[ISSN] 0167-6806

[Journal-full-title] Breast cancer research and treatment

[ISO-abbreviation] Breast Cancer Res. Treat.

[Language] eng

[Publication-type] Journal Article; Randomized Controlled Trial

[Publication-country] Netherlands

[Other-IDs] NLM/ PMC2092407

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] IGFBP3 mRNA expression in benign and malignant breast tumors.

INTRODUCTION: Most previous studies have focused on evaluating the association between circulating insulin-like growth factor binding protein 3 (IGFBP-3) levels and breast cancer risk.

METHODS: To understand the role of IGFBP-3 in breast tumorigenesis, we investigated IGFBP3 mRNA expression levels in benign and malignant breast tumors and their adjacent normal tissues using real-time quantitative PCR.

RESULTS: Cancer tissues had significantly lower IGFBP3 expression than benign tumor tissues (p < 0.001).

IGFBP3 expressions in both tumor and adjacent tissues were higher in patients who had proliferative benign tumors than in those who had non-proliferative benign tumors.

Among patients with benign breast disease, IGFBP3 expression in the tumor was significantly higher than that in their adjacent normal tissue.

There were no apparent associations of IGFBP3 expression in cancer tissues with either overall survival or disease-free survival in a cohort of 521 patients with breast cancer.

CONCLUSION: Our findings suggest that the expression level of IGFBP3 in breast tissues may be involved in breast tumorigenesis.

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Diseases.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Cancer. 2000 Jul 15;87(2):295-300 [10861490.001]

[Cites] Breast Cancer Res Treat. 2007 Sep;105(1):55-61 [17066319.001]

[Cites] Int J Cancer. 2000 Nov 1;88(3):448-53 [11054675.001]

[Cites] Microsc Res Tech. 2002 Oct 1;59(1):12-22 [12242693.001]

[Cites] J Endocrinol. 2002 Oct;175(1):19-31 [12379487.001]

[Cites] J Biol Chem. 2003 Jan 31;278(5):2969-76 [12433918.001]

[Cites] J Clin Pathol. 2003 Aug;56(8):599-604 [12890810.001]

[Cites] Cancer Biol Ther. 2003 Nov-Dec;2(6):630-5 [14688466.001]

[Cites] Cancer Res. 2004 Feb 1;64(3):836-9 [14871809.001]

[Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1950-6 [15070968.001]

[Cites] Lancet. 2004 Apr 24;363(9418):1346-53 [15110491.001]

[Cites] Cancer Res. 1992 Sep 15;52(18):5100-3 [1381277.001]

[Cites] Cancer Res. 1992 Oct 1;52(19):5204-7 [1382838.001]

[Cites] J Biol Chem. 1993 Jul 15;268(20):14964-71 [7686909.001]

[Cites] J Cell Biochem. 1993 Jun;52(2):196-205 [7690042.001]

[Cites] Cancer Lett. 1994 Feb 28;77(1):25-32 [7512885.001]

[Cites] J Clin Endocrinol Metab. 1996 Jan;81(1):411-20 [8550786.001]

[Cites] J Natl Cancer Inst. 1996 May 1;88(9):601-6 [8609661.001]

[Cites] Int J Biochem Cell Biol. 1996 Jun;28(6):619-37 [8673727.001]

[Cites] Br J Cancer. 1996 Oct;74(8):1242-7 [8883411.001]

[Cites] J Biol Chem. 1997 May 2;272(18):12181-8 [9115291.001]

[Cites] J Biol Chem. 1997 Oct 10;272(41):25602-7 [9325280.001]

[Cites] Breast Cancer Res Treat. 1998 Feb;47(3):283-93 [9516082.001]

[Cites] Clin Cancer Res. 1997 Jan;3(1):103-9 [9815544.001]

[Cites] Int J Cancer. 1998 Dec 18;79(6):624-8 [9842972.001]

[Cites] Endocrinology. 1999 Mar;140(3):1319-28 [10067859.001]

[Cites] Breast Cancer Res. 2005;7(1):R119-29 [15642160.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):2-19 [15668470.001]

[Cites] Cancer Res. 2005 Jun 15;65(12):5015-9 [15958542.001]

[Cites] Endocr Relat Cancer. 2006 Jun;13(2):593-605 [16728585.001]

[Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89 [10995803.001]

(PMID = 17210081.001).

[ISSN] 1465-542X

[Journal-full-title] Breast cancer research : BCR

[ISO-abbreviation] Breast Cancer Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA064277; United States / NCI NIH HHS / CA / R01 CA090899; United States / NCI NIH HHS / CA / R01CA64277; United States / NCI NIH HHS / CA / R01CA90899

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / RNA, Messenger

[Other-IDs] NLM/ PMC1851392

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Benign mesenchymal stromal tumor of the breast simulating benign schwannoma in an 81-year-old male--a case report].

[Transliterated title] Benigní vretenobunecný stromální tumor prsu podobný schwannomu u 81letého muze-- kazuistika.

Presented is an unusual case of a benign mesenchymal stromal tumor of the breast in an 81-year-old male.

The basic appearance of the lesion simulated benign schwannoma and was misinterpreted as a low-grade myxoid liposarcoma initially.

Well-circumscribed, gray-white mass measuring 35 mm in maximum diameter was discovered deep in the parenchyma of the completely removed breast.

Microscopically, the lesion consisted of myxoid, richly vascular background where dominated oval or spindle cells with impressive palisading replicating that of benign schwannoma.

On the background of both detailed review and differential diagnosis of benign, so-called stromal tumor of the female breast, the rarity of this microscopic finding in male is documented.

[MeSH-major] Breast Neoplasms, Male / pathology. Liposarcoma, Myxoid / pathology. Neurilemmoma / pathology. Stromal Cells / pathology

[MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Humans. Male

Genetic Alliance. consumer health - Schwannoma.

MedlinePlus Health Information. consumer health - Male Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17171974.001).

[ISSN] 1210-7875

[Journal-full-title] Československá patologie

[ISO-abbreviation] Cesk Patol

[Language] cze

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Czech Republic

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Benign breast lesions in Eastern Nigeria.

OBJECTIVE: To characterize benign breast diseases in Eastern Nigeria and to highlight the age variations of these lesions as base line data.

Seven hundred and twenty-two benign breast specimens were analyzed over 5 years from 1st January 2000 to 31st December 2004, out of 1050 breast samples received.

RESULTS: Of 1050 breast specimens received, 722 (68.8%) were benign.

Normal breast in the axillary tail region was seen in 32 cases (4.4%), represented as no pathology, with a mean presentation age of 20-46 years.

Low grade Phyllodes tumor had 28 cases (3.9%), presenting at an average mean age of 17-32 years.

Benign breast lesions peaked at the 20-24 age range and then declined.

CONCLUSION: Benign breast lesions occur more frequently than malignant breast lesions with a ratio of 2.3:1 and were presented 20 years earlier than their malignant counterparts.

Fibroadenoma was the most common benign lesion followed by fibrocystic disease, similar to the findings in Western Nigeria.

In Northern Nigeria, fibrocystic breast disease was more common.

[MeSH-major] Breast Diseases / epidemiology. Breast Neoplasms / epidemiology. Fibroadenoma / epidemiology

[MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Female. Fibrocystic Breast Disease / epidemiology. Gynecomastia / epidemiology. Humans. Male. Middle Aged. Nigeria / epidemiology. Phyllodes Tumor / epidemiology. Sex Factors

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18246234.001).

[ISSN] 0379-5284

[Journal-full-title] Saudi medical journal

[ISO-abbreviation] Saudi Med J

[Language] eng

[Publication-type] Comparative Study; Evaluation Studies; Journal Article

[Publication-country] Saudi Arabia

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Unusual benign breast lesions.

The purpose of this article is to show examples of the radiological (mammography and/or ultrasound) and pathological appearances of unusual benign breast lesions.

[MeSH-major] Breast Neoplasms / radiography. Breast Neoplasms / ultrasonography

[MeSH-minor] Fasciitis / radiography. Fasciitis / ultrasonography. Female. Fibroma / radiography. Fibroma / ultrasonography. Granular Cell Tumor / radiography. Granular Cell Tumor / ultrasonography. Hemangioma / radiography. Hemangioma / ultrasonography. Humans. Leiomyoma / radiography. Leiomyoma / ultrasonography. Mammography / methods. Neoplasms, Muscle Tissue / radiography. Neoplasms, Muscle Tissue / ultrasonography. Neurofibroma / radiography. Neurofibroma / ultrasonography. Ultrasonography, Mammary / methods

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16784941.001).

[ISSN] 0009-9260

[Journal-full-title] Clinical radiology

[ISO-abbreviation] Clin Radiol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 26

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Benign myoepithelioma of the breast: origin and development.

A case of benign myoepithelioma of the breast in a 55-year-old woman is described.

The tumor was a well-circumscribed solid mass, measuring 13 x 12 mm.

Histopathology indicated that the tumor was composed of entirely myoepithelial cells, which was confirmed by immunoreactivity to calponin and S-100.

There was no ductal differentiation in the tumor, and staining for pan-cytokeratin and epithelial membrane antigen was weak and negative, respectively.

Although the biological behavior of the tumor remains to be ascertained, the tumor was considered to be myoepithelioma with benign features due to mild nuclear pleomorphism, sparse mitotic figures, low Ki-67 labeling index and low S-phase fraction.

Diagnostic confusion between benign myoepithelioma and other myoepithelial-rich cell tumors is possible.

Considering the classification of myoepithelial tumor in the salivary glands, benign myoepithelioma of the breast may possess a different development process from adenomyoepithelioma.

[MeSH-major] Breast Neoplasms / pathology. Myoepithelioma / pathology

[MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Mastectomy. Middle Aged

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19490475.001).

[ISSN] 1440-1827

[Journal-full-title] Pathology international

[ISO-abbreviation] Pathol. Int.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Australia

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Phyllodes tumor and pregnancy. A report of a case].

[Transliterated title] Tumor phyllodes y embarazo. Reporte de un caso.

Phyllodes tumor is a rare breast fibroepithelial neoplasm of the breast, predominant in females (0.3 to 0.5%).

Phyllodes tumor during pregnancy grows fast and its size is relatively big.

These tumors can be classified as benign, malignant or neighboring.

A 32-year-old patient at 23.4 week of gestation was admitted in the National Institute of Perinatology with a rapidly growing mass in the right breast; diagnosis confirmed by ultrasound study reporting echoic images on right breast, 10 x 10 cm the greatest and 3x3 cm the smallest.

A simple mastectomy was performed at the 26.6 week of gestation on the right breast.

A possible phyllodes tumour in the right breast was observed during surgery, weight 9.6 pounds, with partial infiltration to major pectoral muscle.

Pathology reported a benign phyllodes tumor in the right breast, with surgical borders free of tumor.

Phyllodes tumor is rare and can occur during pregnancy.

It is unknown if the tumor is hormone-dependent.

The growth of a tumor on a subsequent pregnancy is not necessarily associated with recurrency or with a new disorder on the patient, who has had a complete excision.

[MeSH-major] Breast Neoplasms. Phyllodes Tumor. Pregnancy Complications, Neoplastic

[MeSH-minor] Adult. Female. Humans. Pregnancy

Genetic Alliance. consumer health - Phyllodes Tumor.

Genetic Alliance. consumer health - Pregnancy.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16304962.001).

[ISSN] 0300-9041

[Journal-full-title] Ginecología y obstetricia de México

[ISO-abbreviation] Ginecol Obstet Mex

[Language] spa

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Mexico

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Phyllodes tumor in a pediatric patient. Case report and literature review].

[Transliterated title] Tumor phyllodes en un paciente pediátrico. Informe de un caso y revisión de la literatura.

We present a phyllodes tumor in an 11-year-old female and we reviewed the literature regarding this pathology.

CASE REPORT: We present the case of an 11-year-old female with a diagnosis of phyllodes tumor.

Histological report demonstrated benign phyllodes tumor.

[MeSH-major] Breast Neoplasms. Phyllodes Tumor

[MeSH-minor] Child. Female. Humans. Mastectomy

Genetic Alliance. consumer health - Phyllodes Tumor.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18492439.001).

[ISSN] 0009-7411

[Journal-full-title] Cirugía y cirujanos

[ISO-abbreviation] Cir Cir

[Language] spa

[Publication-type] Case Reports; English Abstract; Journal Article; Review

[Publication-country] Mexico

[Number-of-references] 36

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pleomorphic adenoma (benign mixed tumor) of the breast: a case report and review of the literature.

We report a case of pleomorphic adenoma (benign mixed tumor) of the breast, which is an extremely rare location for this tumor.

Examination of a 55-year-old woman unexpectedly revealed a mass measuring 0.8 cm in diameter in the subareolar region of the right breast.

Excisional biopsy was performed, and the tumor histologically showed pleomorphic adenoma composed of duct epithelial cells, myoepithelial cells, and a myxochondroid matrix.

Sixty-nine cases of this type of tumor arising in the breast have been described previously.

Using imaging procedures, the tumor has occasionally been misdiagnosed as malignant clinically and even pathologically in frozen section diagnosis.

Careful diagnosis based on paraffin sections is required to avoid unnecessary aggressive surgery, and pathologists should include pleomorphic adenoma in the differential diagnosis of a demarcated, juxtaareolar, small hard mass.

[MeSH-major] Adenoma, Pleomorphic / pathology. Breast Neoplasms / pathology

[MeSH-minor] Biomarkers, Tumor / analysis. Female. HMGA1a Protein / analysis. HMGA2 Protein / analysis. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Middle Aged. Receptors, Estrogen / analysis

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15991841.001).

[ISSN] 0344-0338

[Journal-full-title] Pathology, research and practice

[ISO-abbreviation] Pathol. Res. Pract.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] Germany

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HMGA2 Protein; 0 / Receptors, Estrogen; 124544-67-8 / HMGA1a Protein

[Number-of-references] 32

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparison of some trace elements concentration in blood, tumor free breast and tumor tissues of women with benign and malignant breast lesions: an Indian study.

Fifty women residing in and around New Delhi, India and identified to have benign (25 nos.) and malignant (25 nos.) breast lesions were studied for the first time to access the association between environmental exposure to lead and risk of breast cancer and to determine the potential of changes in trace elements concentration as a diagnostic marker and/or its etiological involvement in the disease.

Blood, tumor tissue and breast adipose tissue from tumor free area from each patient of the two groups, collected at the time of lumpectomy or mastectomy (only blood sample was collected from disease free control group), were analyzed to determine the concentration of Pb, Zn, Cu, Fe and Ca using Atomic Absorption Spectrometry.

Blood lead was significantly higher in malignant cases than in those of benign and control (p<0.05 each).

Lead level was also higher in tumor tissue when compared with their respective normal tumor free breast tissue, though non-significant, in both benign and malignant cases.

Interestingly, Zn, Fe, and Ca levels were higher in blood of malignant cases than in those of their benign counterparts.

Furthermore, these metals were also higher in tumor of malignant and benign cases as compared to normal tumor free breast tissue, many of them statistically significant (p<0.05/0.01/0.001).

However, Cu level was insignificantly lower in the blood and tumor tissue of malignant cases when compared with their benign counterparts while it was significantly higher (p<0.05) in tumor of benign cases when compared with those of their respective normal tumor free breast tissue.

There were statistically significant correlations between lead and trace element levels only in normal tumor free breast tissue of benign and malignant cases (r=0.41-0.73; p<0.05-0.001) but neither in blood nor tumor tissue of the two groups.

These results suggest that in the backdrop of existing experimental and epidemiological evidences exposure to lead may be one of the risk factors for breast lesions; though it warrants further investigation.

Further, modulation of trace elements level in both benign and malignant breast diseases patients may be of potential to be used as diagnostic marker of the disease process and its possible relationship etiologically.

[MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Mammary Glands, Human / metabolism. Trace Elements / blood

[MeSH-minor] Adult. Female. Humans. India. Middle Aged. Risk Factors. Spectrometry, X-Ray Emission

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16580070.001).

[ISSN] 0160-4120

[Journal-full-title] Environment international

[ISO-abbreviation] Environ Int

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Trace Elements

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Neuroendocrine tumor of the breast.

Mammary carcinoid is an uncommon neoplasm.

It accounts for approximately 5 per cent of all breast carcinomas.

However, it is still controversial whether mammary carcinoid tumors should be considered a distinct clinical entity or be treated as a variant of conventional breast carcinoma.

Differentiating these lesions from benign lesions such as epithelial hyperplasia and papillomas can be challenging at times.

We present a case of neuroendocrine tumor of the breast.

[MeSH-major] Breast Neoplasms / pathology. Carcinoid Tumor / pathology. Carcinoma, Ductal, Breast / pathology

[MeSH-minor] Adult. Female. Humans

Genetic Alliance. consumer health - Pancreatic islet cell tumors.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16536254.001).

[ISSN] 0003-1348

[Journal-full-title] The American surgeon

[ISO-abbreviation] Am Surg

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Wavelet-based characterization of spectral fluctuations in normal, benign, and cancerous human breast tissues.

Fluorescence intensity fluctuations in the visible wavelength regime in normal, benign, and cancerous human breast tissue samples are studied through wavelet transform.

Furthermore, for cancerous tissues, the same is very well described by the normal distribution, which is not the case for normal and benign samples.

The differences in the average, low-pass wavelet coefficients of normal, cancerous, pericanalicular, and intracanalicular benign tissues are also pointed out.

[MeSH-major] Algorithms. Artificial Intelligence. Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Breast Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Spectrometry, Fluorescence / methods

[MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Signal Processing, Computer-Assisted

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16292972.001).

[ISSN] 1083-3668

[Journal-full-title] Journal of biomedical optics

[ISO-abbreviation] J Biomed Opt

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast?

The immunohistochemical detection of myoepithelial cells in benign sclerosing lesions of the breast is useful in distinguishing them from tubular carcinoma.

The authors assessed the use of p63 and CD10 in the differential diagnosis between benign sclerosing lesions, such as sclerosing adenosis and radial scar, and tubular carcinoma, in comparison to the traditional myoepithelial markers 1A4 and calponin. p63, CD10, 1A4, and calponin were expressed in myoepithelial cells of all benign lesions and were consistently negative in all cases of tubular carcinoma.

In conclusion, p63 and CD10 may be used as a complement to 1A4 in distinguishing benign sclerosing lesions from tubular carcinoma of the breast.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16540734.001).

[ISSN] 1541-2016

[Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM

[ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 3.4.24.11 / Neprilysin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.

Mammaglobin (MGB), a secretory protein belonging to the uteroglobin/Clara cell protein family, is a sensitive marker for breast carcinoma, but is also reported to be expressed in the female genital tract and its neoplasms.

Details of MGB expression pattern and its pathologic significance in the female genital tract have not been systematically studied.

Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.

Reduction of MGB staining was seen in transition from benign epithelium to AIS.

These results confirm that MGB is not specific for breast carcinoma, but is also variably expressed in nonneoplastic and neoplastic endocervical and endometrial tissues.

Most endocervical adenocarcinomas are negative for MGB, in contrast to mostly positive endometrioid endometrial adenocarcinomas, however, MGB expression alone is not specific enough to distinguish these 2 tumor types.

[MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism

[MeSH-minor] Cervix Uteri / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Female. Humans. Immunohistochemistry. Mammaglobin A. Uterine Cervical Neoplasms / metabolism

MedlinePlus Health Information. consumer health - Uterine Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18580321.001).

[ISSN] 1538-7151

[Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists

[ISO-abbreviation] Int. J. Gynecol. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Breast fibromatosis: An uncommon benign breast disease].

[Transliterated title] La fibromatose mammaire : une lésion bénigne peu connue.

Extra-abdominal fibromatosis is an uncommon benign breast lesion resembling an infiltrative carcinoma in its clinical and radiological presentation.

Surgical excision with wide margins remains the treatment of choice to avoid recurrence of this locally aggressive tumor.

We present a case in which surgical biopsy allowed the diagnosis of a breast fibromatosis and we discuss its clinical, diagnostic, pathological and therapeutic particularities.

[MeSH-major] Breast Diseases / pathology. Fibroma / pathology

[MeSH-minor] Female. Genes, APC. Humans. Middle Aged. Postmenopause

Genetic Alliance. consumer health - Fibromatosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19362506.001).

[ISSN] 1297-9589

[Journal-full-title] Gynécologie, obstétrique & fertilité

[ISO-abbreviation] Gynecol Obstet Fertil

[Language] fre

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] France

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Benign phylloides tumor of the breast. Considerations on a clinical case].

[Transliterated title] Tumore fillode gigante benigno della mammella. Considerazioni a proposito di un caso clinico.

Phyllodes tumors are unusual biphasic fibroepithelial neoplasms of the breast, accounting for < 1% of all breast tumors and raising issues of diagnosis and therapeutic choice.

Core tissue biopsy or incisional biopsy represent the preferred means of pre-operative diagnosis.

Conservative treatment can be effective also in giant tumors depending upon the size of the tumor and the breast if a complete excision with an adequate margin of normal breast tissue can be achieved, so avoiding local recurrence often accompanied by worse histopathology.

The Authors report the case of a giant benign phyllode tumor of the breast treated with conservative surgery, quadrantectomy and oncoplasty.

[MeSH-major] Breast Neoplasms. Phyllodes Tumor

[MeSH-minor] Adult. Female. Humans

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20476682.001).

[ISSN] 0003-469X

[Journal-full-title] Annali italiani di chirurgia

[ISO-abbreviation] Ann Ital Chir

[Language] ita

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Italy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor-like disorders.

BACKGROUND: Although many reports indicated an association between thyroid diseases and breast cancer, such an association still remains controversial.

The present study was aimed to clarify the association of thyroid diseases with the breast cancer incidence.

In the patients with benign and malignant thyroid tumor or tumor-like disorders, the incidence of other malignancies was surveyed, and the frequency of thyroid cancer in patients with breast cancer was also surveyed.

PATIENTS AND METHODS: Between 1982 and 2005, a total of 201 female patients received surgery for tumor or tumor-like disorders, including 65 carcinoma, 68 adenoma, 61 adenomatous goiter and 7 chronic thyroiditis cases.

Furthermore, during the same periods, 340 female patients underwent breast cancer surgery and their outcomes were also surveyed in December 2006.

RESULTS: The overall incidence rate of breast cancer was 16.4% (33/201) in the patients, who received thyroid surgeries and was much higher than other malignancies: 2.0% gastric cancer, 1.0% uterine and colorectal cancer.

The incidence rate of breast cancer in each disease was 13.8% for thyroid cancer, 16.2% for adenoma and 21.3% for adenomatous goiter, but no incidence for chronic thyroiditis.

On the other hand, in the patients with breast cancer during the same period in our department, the frequency of thyroid cancer was only 2.1% (7/340).

CONCLUSION: It appears that thyroid cancer, adenoma and adenomatous goiter were associated with the risk of breast cancer, but chronic thyroiditis was not related.

[MeSH-major] Breast Neoplasms / epidemiology. Neoplasms, Second Primary / complications. Thyroid Neoplasms / complications

[MeSH-minor] Female. Humans. Incidence

Genetic Alliance. consumer health - Breast Cancer.

Genetic Alliance. consumer health - Thyroid Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19443373.001).

[ISSN] 0250-7005

[Journal-full-title] Anticancer research

[ISO-abbreviation] Anticancer Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Greece

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Management of benign tumors of the adolescent breast.

Describe the differential diagnosis of breast tumors in adolescent girls.

2. Compare and contrast surgical options for the management of adolescent breast tumors.

SUMMARY: Although 99 percent of breast lesions in female adolescents are benign tumors, surgical intervention is commonly required.

This article reviews the differential diagnosis, evaluation, and management of these benign tumors.

A modified surgical technique for resection of large fibroadenomas and reconstruction of the remaining breast is described.

The authors review the approach to five specific breast lesions: fibroadenomas, phyllodes tumors, juvenile hypertrophy, inflammatory processes, and premature breast development.

[MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Mammaplasty / methods

[MeSH-minor] Adolescent. Age Factors. Biopsy, Needle. Esthetics. Female. Fibroadenoma / pathology. Fibroadenoma / surgery. Follow-Up Studies. Humans. Immunohistochemistry. Mastectomy / methods. Phyllodes Tumor / pathology. Phyllodes Tumor / surgery. Risk Factors. Treatment Outcome

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Plast Reconstr Surg. 2008 Aug;122(2):679-80 [18626406.001]

(PMID = 17572540.001).

[ISSN] 1529-4242

[Journal-full-title] Plastic and reconstructive surgery

[ISO-abbreviation] Plast. Reconstr. Surg.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 26

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] DNA methylation in benign breast epithelium in relation to age and breast cancer risk.

BACKGROUND: Many established breast cancer risk factors are related to the timing and duration of exposure to reproductive hormones, which are known to drive breast epithelial cell proliferation.

The epigenetic molecular clock hypothesis suggests that CpG island methylation records the cell division history of benign epithelium.

In proliferative epithelium, such as breast, this may provide an individualized cell-based measure of cancer risk.

METHODS: Methylation of cyclin D2, APC, HIN1, RASSF1A, and RAR-beta2 was measured by quantitative multiplex methylation-specific PCR in 290 benign and malignant breast epithelial cell samples obtained by palpation-directed fine-needle aspiration biopsy from 164 women.

Univariate, multivariate, and unsupervised cluster analysis was used to establish the relationship between TSG methylation and a personal history of breast cancer, predicted breast cancer risk, and specific breast cancer risk factors.

RESULTS: RASSF1A methylation was highly correlated with breast cancer risk [odds ratio (OR), 5.28; 95% confidence interval (95% CI), 1.95-14.32; P = 0.001], atypical cytology (OR, 4.11; 95% CI, 1.30-12.98; P = 0.016), and benign breast disease requiring biopsy (OR, 6.12; 95% CI, 1.41-26.51; P = 0.016).

CONCLUSIONS: TSG methylation increases in benign breast epithelium with increasing age.

Because it is independently related to a personal history of benign or malignant breast disease and to predicted breast cancer risk, it may have value for breast cancer risk stratification and as a surrogate endpoint marker in prevention trials.

[MeSH-major] Breast Neoplasms / genetics. DNA Methylation

[MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Breast / pathology. Cluster Analysis. CpG Islands / genetics. Cyclin D2. Cyclins / genetics. Cytokines / genetics. Epithelium / pathology. Female. Genes, APC. Humans. Middle Aged. Multivariate Analysis. Polymerase Chain Reaction. Receptors, Retinoic Acid / genetics. Risk Factors. Tumor Suppressor Proteins / genetics

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18483325.001).

[ISSN] 1055-9965

[Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

[ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / Cytokines; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / SCGB3A1 protein, human; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast.

The expression of the extracellular matrix-related genes, such as fibronectin, laminin and tenascin C, and apoptosis-related genes, such as bax, bcl2 and survivin, was evaluated by reverse transcription-polymerase chain reaction (RT-PCR) and by immunohistochemistry in normal breast tissue and benign and malignant breast tumors and then correlated to several clinical parameters: estrogen and progesterone receptors, Ki67, ErbB2, tumor size, lymph node status and grading.

Seventy-three breast tissue samples were examined.

The negative correlation between laminin transcription and Ki67 could suggest that laminin impacts negatively on tumor proliferation, and the positive correlation between fibronectin and lymph node status may lead to consider fibronectin as predictive of long distance metastasis.

[MeSH-major] Apoptosis. Biomarkers, Tumor. Breast Diseases / metabolism. Breast Neoplasms / metabolism. Carcinoma / metabolism. Extracellular Matrix / metabolism. Gene Expression Regulation. Gene Expression Regulation, Neoplastic

[MeSH-minor] Cell Differentiation. Cell Line, Tumor. Cell Proliferation. Cytoplasm / metabolism. Female. Fibronectins / metabolism. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Ki-67 Antigen / biosynthesis. Laminin / metabolism. Lymphatic Metastasis. Microtubule-Associated Proteins / metabolism. Neoplasm Metastasis. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. RNA / metabolism. Receptor, ErbB-2 / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tenascin / metabolism. bcl-2-Associated X Protein / metabolism

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Diseases.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16142317.001).

[ISSN] 1019-6439

[Journal-full-title] International journal of oncology

[ISO-abbreviation] Int. J. Oncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Greece

[Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Laminin; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tenascin; 0 / bcl-2-Associated X Protein; 63231-63-0 / RNA; EC 2.7.10.1 / Receptor, ErbB-2

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunohistochemical detection of telomerase reverse transcriptase (TERT) protein in benign and malignant tumor cells of the breast.

In this study, the expression of TERT was investigated by immunocytochemistry to determine whether it is a useful marker for differential diagnosis in benign or malignant breast tumors.

We examined imprint smears prepared from 63 surgically resected breast lesions, and 27 cases of secretion or aspiration cytology smears had been routinely diagnosed.

In conclusion, the expression of TERT protein might be a useful marker for differential diagnosis in malignant and benign breast tumors.

[MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. DNA-Binding Proteins / analysis. Telomerase / analysis

[MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. In Situ Hybridization. RNA, Messenger / analysis

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] Rinsho Byori.2005 Aug;53(8):748

(PMID = 16026073.001).

[ISSN] 0047-1860

[Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology

[ISO-abbreviation] Rinsho Byori

[Language] eng

[Publication-type] Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Rapid noninvasive optical imaging of tissue composition in breast tumor margins.

BACKGROUND: In women undergoing breast conserving surgery (BCS), up to 60% can require re-excision.

Our objective is to develop an optically based technology which can differentiate benign from malignant breast tissues intraoperatively through differences in tissue composition factors.

Within 34 specimens with pathologically confirmed positive margins, the ratio map of b-carotene/scattering showed the most significant difference reflecting a decrease in adipose and an increase in cell density within malignant margins (p=.002).

CONCLUSIONS: We present a novel optical spectral imaging device that provides a rapid, non-destructive assay of the tissue composition of breast tumor margins.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Arch Pathol Lab Med. 2002 Jul;126(7):846-8 [12088456.001]

[Cites] Curr Opin Biotechnol. 2009 Feb;20(1):119-31 [19268567.001]

[Cites] Am J Surg. 2002 Nov;184(5):383-93 [12433599.001]

[Cites] Cancer. 2003 Aug 15;98(4):697-702 [12910512.001]

[Cites] CA Cancer J Clin. 1999 May-Jun;49(3):159-77 [10445015.001]

[Cites] Eur J Surg Oncol. 2004 Dec;30(10):1058-64 [15522551.001]

[Cites] AJR Am J Roentgenol. 2005 Jan;184(1):324-9 [15615996.001]

[Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]

[Cites] J Am Coll Surg. 2005 Aug;201(2):194-8 [16038815.001]

[Cites] Am J Surg Pathol. 2005 Dec;29(12):1625-32 [16327435.001]

[Cites] Lancet. 2005 Dec 17;366(9503):2087-106 [16360786.001]

[Cites] Appl Opt. 2006 Feb 10;45(5):1062-71 [16512550.001]

[Cites] Appl Opt. 2006 Feb 10;45(5):1072-8 [16512551.001]

[Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]

[Cites] Am J Surg. 2006 Oct;192(4):509-12 [16978962.001]

[Cites] Am J Surg. 2006 Oct;192(4):538-40 [16978970.001]

[Cites] Ann Surg Oncol. 2007 Apr;14(4):1458-71 [17260108.001]

[Cites] Ann Surg Oncol. 2007 Oct;14(10):2953-60 [17674109.001]

[Cites] Ann Surg Oncol. 2007 Nov;14(11):3133-40 [17653798.001]

[Cites] J Am Coll Surg. 2008 Jan;206(1):76-82 [18155571.001]

[Cites] Ann Surg Oncol. 2008 May;15(5):1297-303 [18259820.001]

[Cites] Ann Surg Oncol. 2008 May;15(5):1271-2 [18320287.001]

[Cites] Cancer. 2008 May 1;112(9):1923-31 [18327818.001]

[Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024012 [18465975.001]

[Cites] J Am Coll Surg. 2008 Jun;206(3):1116-21 [18501808.001]

[Cites] J Biomed Opt. 2008 May-Jun;13(3):034015 [18601560.001]

[Cites] Ann Surg Oncol. 2008 Sep;15(9):2542-9 [18618180.001]

[Cites] Am J Surg. 2008 Oct;196(4):556-8 [18809063.001]

[Cites] World J Surg. 2008 Dec;32(12):2599-606 [18836763.001]

[Cites] Eur J Surg Oncol. 2009 Jan;35(1):32-7 [18539425.001]

[Cites] Breast Cancer Res Treat. 2009 Jan;113(2):397-402 [18386174.001]

[Cites] J Biomed Opt. 2009 Jan-Feb;14(1):014024 [19256712.001]

[Cites] J Clin Oncol. 2009 Apr 1;27(10):1615-20 [19255332.001]

[Cites] Cancer Res. 2009 Apr 1;69(7):2919-26 [19293184.001]

[Cites] Cancer. 2009 Apr 15;115(8):1669-79 [19170229.001]

[Cites] Am J Surg. 2002 Aug;184(2):89-93 [12169349.001]

(PMID = 19800470.001).

[ISSN] 1879-1883

[Journal-full-title] American journal of surgery

[ISO-abbreviation] Am. J. Surg.

[Language] ENG

[Grant] United States / NCRR NIH HHS / RR / UL1 RR024128; United States / NCRR NIH HHS / RR / UL1 RR024128-01; United States / NCRR NIH HHS / RR / 1UL1 RR024128-01

[Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Other-IDs] NLM/ NIHMS137679; NLM/ PMC2764289

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells.

The effects of progesterone on breast epithelial cells remain poorly defined with observations showing both proliferative and antiproliferative effects.

The release of paracrine growth factors from nuclear receptor-positive cells has been postulated as a mechanism, since in vitro studies show a lack of growth effect by progesterone in breast epithelial cells lacking nuclear receptors.

This study examined possible nongenomic effects of progesterone in breast epithelia by using MCF-10A cells known to lack nuclear progesterone receptor expression.

Our study demonstrates a nongenomic action of progesterone on benign breast epithelial cells, resulting in enhanced cellular respiration and protection from apoptosis.

MedlinePlus Health Information. consumer health - Breast Cancer.

Hazardous Substances Data Bank. PROGESTERONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Mol Cell Cardiol. 1995 Oct;27(10):2167-76 [8576933.001]

[Cites] Genes Dev. 1995 Sep 15;9(18):2266-78 [7557380.001]

[Cites] Breast Cancer Res Treat. 1997 Sep;45(2):121-33 [9342437.001]

[Cites] Exp Cell Res. 1997 Oct 10;236(1):223-30 [9344602.001]

[Cites] Cancer Res. 1997 Nov 15;57(22):4987-91 [9371488.001]

[Cites] J Biol Chem. 1999 Apr 30;274(18):12567-75 [10212235.001]

[Cites] Breast Cancer Res Treat. 1999 Feb;53(3):217-27 [10369068.001]

[Cites] J Steroid Biochem Mol Biol. 2005 Nov;97(3):278-88 [16154741.001]

[Cites] Dev Cell. 2005 Dec;9(6):843-54 [16326395.001]

[Cites] J Steroid Biochem Mol Biol. 2006 Feb;98(2-3):174-8 [16413775.001]

[Cites] J Biol Chem. 2006 Mar 3;281(9):5837-44 [16407197.001]

[Cites] J Steroid Biochem Mol Biol. 2006 Mar;98(4-5):218-27 [16466914.001]

[Cites] Carcinogenesis. 2006 May;27(5):925-35 [16361271.001]

[Cites] Apoptosis. 2006 Apr;11(4):473-85 [16532373.001]

[Cites] Biochim Biophys Acta. 2006 May-Jun;1757(5-6):509-17 [16829228.001]

[Cites] Maturitas. 2006 Jul 20;54(4):327-34 [16806749.001]

[Cites] Eur J Obstet Gynecol Reprod Biol. 2006 Nov;129(1):77-83 [16460873.001]

[Cites] Mol Endocrinol. 2006 Dec;20(12):3146-64 [16959873.001]

[Cites] FEBS J. 2007 Mar;274(6):1393-418 [17302740.001]

[Cites] Endocrinology. 2007 Jun;148(6):2723-36 [17332059.001]

[Cites] Cell Prolif. 2007 Oct;40(5):721-40 [17877612.001]

[Cites] Biol Chem. 2007 Oct;388(10):1113-9 [17937626.001]

[Cites] Mitochondrion. 2007 Dec;7(6):399-401 [17881297.001]

[Cites] Methods. 2008 Mar;44(3):222-8 [18314052.001]

[Cites] Breast. 2008 Apr;17(2):172-9 [17928227.001]

[Cites] Cell Res. 2009 Jan;19(1):140-8 [19079362.001]

[Cites] J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65 [10599719.001]

[Cites] Cancer Res. 2000 Feb 15;60(4):867-72 [10706096.001]

[Cites] Cancer Res. 2000 Feb 15;60(4):936-43 [10706108.001]

[Cites] Oncology. 2000;59 Suppl 1:39-44 [11096355.001]

[Cites] Mol Endocrinol. 2001 Feb;15(2):255-70 [11158332.001]

[Cites] Mol Cell Endocrinol. 2001 Jun 20;179(1-2):97-103 [11420134.001]

[Cites] Endocrinology. 2002 Aug;143(8):3071-82 [12130573.001]

[Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):93-105 [12160089.001]

[Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]

[Cites] Breast Cancer Res. 2002;4(5):187-90 [12223122.001]

[Cites] Mol Endocrinol. 2003 Jan;17(1):117-27 [12511611.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2231-6 [12574519.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2237-42 [12601167.001]

[Cites] Mol Cell Endocrinol. 2003 Feb 28;200(1-2):155-63 [12644308.001]

[Cites] J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):25-30 [12650698.001]

[Cites] Biochim Biophys Acta. 2004 Jul 23;1658(1-2):141-7 [15282185.001]

[Cites] Proc Natl Acad Sci U S A. 1974 Aug;71(8):2942-5 [4528490.001]

[Cites] Nature. 1975 Feb 27;253(5494):746-7 [1113869.001]

[Cites] Cancer Res. 1978 Aug;38(8):2434-7 [667841.001]

[Cites] Exp Cell Res. 1988 Sep;178(1):143-53 [3409975.001]

[Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]

[Cites] Mol Endocrinol. 1990 Dec;4(12):1833-40 [2082185.001]

[Cites] Cancer Res. 1994 Jan 15;54(2):340-3 [8275464.001]

[Cites] Cancer Res. 1994 Jul 15;54(14):3868-77 [8033109.001]

[Cites] J Exp Med. 1994 Sep 1;180(3):917-23 [8064240.001]

[Cites] Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):123-8 [9024102.001]

(PMID = 19690070.001).

[ISSN] 1522-1555

[Journal-full-title] American journal of physiology. Endocrinology and metabolism

[ISO-abbreviation] Am. J. Physiol. Endocrinol. Metab.

[Language] ENG

[Grant] United States / NICHD NIH HHS / HD / 1R03HD-052770-01

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD95; 0 / Inhibitor of Differentiation Protein 1; 0 / Protein Synthesis Inhibitors; 0 / Receptors, Progesterone; 0 / Transforming Growth Factor beta1; 4G7DS2Q64Y / Progesterone; 8L70Q75FXE / Adenosine Triphosphate; 98600C0908 / Cycloheximide; EC 3.4.21.- / Kallikreins; EC 3.4.22.- / Caspases; EC 3.4.24.- / Matrix Metalloproteinases

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Breast tumor size assessment: comparison of conventional ultrasound and contrast-enhanced ultrasound.

Accurate assessment of tumor size is necessary when selecting patients for breast-conserving surgery.

In the study of breast contrast-enhanced ultrasound (CEUS), we found that tumor size discrepancy between CEUS and conventional ultrasound (US) existed in some breast lesions, for which the reasons are not clear.

Breast CEUS examinations were performed in 104 patients with breast lesions.

The measurement of the 104 breast tumors on conventional US was obtained and compared with the measurement on CEUS.

A difference in measuring tumor size of >3 mm for tumors up to 1.7 cm and 4 mm for tumors >or=1.7 cm, was defined as a significant discrepancy between conventional US and CEUS.

The histopathological examination of size discrepancy was performed and the margin characteristics of breast cancers with larger measurements were compared with those with unchanged measurements.

Among the 104 lesions (43 malignant, 60 benign, 1 borderline), the size of 27 breast cancers and one granulomatous mastitis appeared larger at CEUS.

Pathologic examinations of the region corresponding to the measurement discrepancy were mainly ductal carcinomas in situ (DCIS), invasive carcinoma with a DCIS component, adenosis with lobular hyperplasia in breast cancers and inflammatory cell infiltration in one granulomatous mastitis.

Well-defined margin characteristics were significantly different between breast cancers with larger measurements at CEUS and those with unchanged measurements of size (p = 0.002), whereas no significant difference was found between the two groups in ill-defined, spiculated, hyperechoic halo, microlobulated and angulated margins (p = 0.463, 0.117, 0.194, 0.666 and 0.780, respectively).

This initial study suggests that significant discrepancy of breast lesion measurement between conventional US and CEUS is more likely presented in breast cancer than benign lesions.

The pathologic findings corresponding to the region of size increased at CEUS are malignant in most malignant lesions and benign in benign lesions.

It is difficult to predict whether the size measurement of the breast cancer increases at CEUS based on the margin characteristics showed on conventional US.

[MeSH-major] Breast Neoplasms / ultrasonography

[MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Diseases / pathology. Breast Diseases / ultrasonography. Contrast Media. Female. Humans. Image Interpretation, Computer-Assisted / methods. Middle Aged. Neoplasm Staging. Phospholipids. Reproducibility of Results. Sulfur Hexafluoride

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17686569.001).

[ISSN] 0301-5629

[Journal-full-title] Ultrasound in medicine & biology

[ISO-abbreviation] Ultrasound Med Biol

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump.

An unusual combination of two benign breast neoplasms adenomyoepithelioma and phyllodes tumor presenting as a solitary breast lump have been described.

This patient also presented with a recurrent breast neoplasm.

[MeSH-major] Adenomyoma / pathology. Breast Neoplasms / pathology. Myoepithelioma / pathology. Neoplasms, Multiple Primary / pathology. Phyllodes Tumor / pathology

[MeSH-minor] Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology

Genetic Alliance. consumer health - Phyllodes Tumor.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] Indian J Pathol Microbiol. 2006 Jul;49(3):476

(PMID = 16933731.001).

[ISSN] 0377-4929

[Journal-full-title] Indian journal of pathology & microbiology

[ISO-abbreviation] Indian J Pathol Microbiol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] India

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Fast edge extraction for ultrasound image of breast tumor based on fuzzy number].

An accurate edge extraction method for the ultrasound breast tumor image is useful for classifying tumors as benign or malignant.

This paper refers to a fast technique to extract edge of breast tumor from ultrasound image.

Experiments of benign and malignant breast tumor in ultrasound images have shown that our method can extract the breast tumor edge faster than many conventional methods can do separately, and the results are reliable and credible.

Our experiments demonstrate that it can be efficiently used to extract the edge of breast tumor from the ultrasound image.

[MeSH-major] Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods

[MeSH-minor] Female. Fuzzy Logic. Humans

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16856374.001).

[ISSN] 1001-5515

[Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi

[ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer.

Invasive breast cancer represents the endpoint of a developmental process that originates in the terminal duct lobular units and is believed to progress through stages of increasing proliferation, atypical hyperplasia, and carcinoma in situ before the cancer acquires invasive and metastatic capabilities.

By comparison with invasive breast cancer, which has been studied extensively, the preceding stages of benign breast disease are more poorly understood.

Much less is known about the molecular changes underlying benign breast disease development and progression, as well as the transition from in situ into invasive disease.

More challenges are posed by limitations of the models used to investigate the lesions preceding invasive breast cancer.

However, recent studies have identified alterations in stromal cell function that may be critical for disease progression from benign disease to invasive cancer: key functions of myoepithelial cells that maintain tissue structure are lost, while tissue fibroblasts become activated to produce proteases that degrade the extracellular matrix and trigger the invasive cellular phenotype.

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Diseases.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 [12714683.001]

[Cites] Cancer Res. 2004 Jan 15;64(2):590-8 [14744773.001]

[Cites] Med Hypotheses. 1997 Jan;48(1):37-46 [9049988.001]

[Cites] J Natl Cancer Inst. 1998 May 6;90(9):697-703 [9586667.001]

[Cites] Clin Cancer Res. 1997 Nov;3(11):1949-58 [9815584.001]

[Cites] Virchows Arch. 1999 Mar;434(3):227-34 [10190302.001]

[Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]

[Cites] J Theor Biol. 2005 Jan 21;232(2):179-89 [15530488.001]

[Cites] J Am Coll Surg. 2005 Mar;200(3):328-35 [15737842.001]

[Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]

[Cites] PLoS Biol. 2005 Jun;3(6):e187 [15869330.001]

[Cites] Cancer Res. 2005 Jul 15;65(14):6130-8 [16024614.001]

[Cites] N Engl J Med. 2005 Jul 21;353(3):275-85 [16034013.001]

[Cites] Nat Genet. 2005 Aug;37(8):899-905 [16007089.001]

[Cites] Breast Cancer Res. 2005;7(5):190-7 [16168137.001]

[Cites] Ann Intern Med. 2005 Sep 20;143(6):446-57 [16172443.001]

[Cites] Cell Cycle. 2005 Aug;4(8):1022-5 [16082203.001]

[Cites] Cancer Res. 2006 Jan 1;66(1):29-33 [16397211.001]

[Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]

[Cites] Cancer Res. 2006 May 15;66(10):5278-86 [16707453.001]

[Cites] Oncologist. 2006 May;11(5):435-49 [16720843.001]

[Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47 [16807803.001]

[Cites] Breast Cancer Res. 2006;8(5):R58 [17054791.001]

[Cites] Breast Cancer Res. 2006;8(5):R61 [17069663.001]

[Cites] J Clin Oncol. 2007 Jul 1;25(19):2671-7 [17563394.001]

[Cites] Rev Endocr Metab Disord. 2007 Sep;8(3):279-87 [17447144.001]

[Cites] J Pathol. 2008 Feb;214(3):357-67 [18044827.001]

[Cites] Clin Cancer Res. 2008 Jan 15;14(2):370-8 [18223211.001]

[Cites] Cancer. 2008 May 15;112(10):2130-42 [18383519.001]

[Cites] Cancer Cell. 2008 May;13(5):394-406 [18455123.001]

[Cites] Breast Cancer Res Treat. 2008 May;109(2):189-98 [17624587.001]

[Cites] Nat Med. 2008 May;14(5):518-27 [18438415.001]

[Cites] Lab Invest. 2008 Jun;88(6):591-601 [18414401.001]

[Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4257-64 [10628384.001]

[Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1185-6 [10904098.001]

[Cites] Breast Cancer Res Treat. 2000 Dec;64(3):235-40 [11200773.001]

[Cites] Breast Cancer Res Treat. 2001 Jan;65(2):101-10 [11261825.001]

[Cites] Endocr Relat Cancer. 2001 Mar;8(1):47-61 [11350726.001]

[Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):39-50 [11801722.001]

[Cites] J Clin Oncol. 2003 Jan 1;21(1):41-5 [12506168.001]

[Cites] Cancer. 2003 Apr 1;97(7):1601-8 [12655515.001]

[Cites] Clin Cancer Res. 2008 Sep 1;14(17):5357-67 [18765527.001]

[Cites] Breast Cancer Res. 2008;10(5):R87 [18928525.001]

[Cites] J Clin Oncol. 2009 Jan 10;27(2):279-88 [19064970.001]

[Cites] Am J Surg Pathol. 2009 Feb;33(2):227-32 [18936688.001]

[Cites] Clin Cancer Res. 2009 Feb 1;15(3):778-87 [19188147.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3372-7 [19218449.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7022-7 [19369208.001]

[Cites] Breast Cancer Res. 2009;11(1):R7 [19187537.001]

[Cites] Breast Cancer Res. 2009;11(1):101 [19291276.001]

[Cites] Breast Cancer Res. 2009;11 Suppl 3:S16 [20030867.001]

[Cites] J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):201-12 [20440544.001]

[Cites] Mol Oncol. 2010 Jun;4(3):192-208 [20452298.001]

[Cites] Breast Cancer Res Treat. 2010 Sep;123(2):397-404 [19949854.001]

[Cites] Histopathology. 2010 Aug;57(2):171-92 [20500230.001]

[Cites] Cancer. 2010 Nov 1;116(21):4944-53 [20645399.001]

[Cites] J Pathol. 2011 Jan;223(2):307-17 [21125683.001]

[Cites] FEBS J. 2011 Jan;278(1):16-27 [21087457.001]

[Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):379-91 [14973383.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]

[Cites] N Engl J Med. 2004 Apr 1;350(14):1430-41 [15070793.001]

[Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]

[Cites] J Natl Cancer Inst. 1973 May;50(5):1111-8 [4123242.001]

[Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]

[Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]

[Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]

[Cites] JAMA. 1992 Feb 19;267(7):941-4 [1734106.001]

[Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1725-32 [8411256.001]

[Cites] Eur J Cancer Prev. 1993 Nov;2 Suppl 3:67-76 [7507749.001]

[Cites] J Natl Cancer Inst. 1994 Apr 20;86(8):614-9 [7511693.001]

[Cites] J Cell Biochem Suppl. 1996;25:112-22 [9027607.001]

(PMID = 21161341.001).

[ISSN] 1573-7039

[Journal-full-title] Journal of mammary gland biology and neoplasia

[ISO-abbreviation] J Mammary Gland Biol Neoplasia

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA116201; United States / NCI NIH HHS / CA / CA90628-08; United States / NCI NIH HHS / CA / CA122086; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / CA132879; United States / NCI NIH HHS / CA / CA128660; United States / NCI NIH HHS / CA / R21 CA128660; United States / NCI NIH HHS / CA / P50 CA116201; United States / NCI NIH HHS / CA / R01 CA132879; United States / NCI NIH HHS / CA / R01 CA122086

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Other-IDs] NLM/ PMC3011086

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Quantitative evaluation of DNA hypermethylation in malignant and benign breast tissue and fluids.

The assessment of DNA had demonstrated altered methylation in malignant compared to benign breast tissue.

The purpose of our study was to (i) confirm the predictive ability of methylation assessment in breast tissue, and (ii) use the genes found to be cancer predictive in tissue to evaluate the diagnostic potential of hypermethylation assessment in nipple aspirate fluid (NAF) and mammary ductoscopic (MD) samples.

Methylation of CCND-2, p16, RAR-beta and RASSF-1a was significantly more prevalent in tumor than in normal tissue specimens.

Methylation frequency was higher in MD specimens from breasts with cancer than benign samples for p16 and RASSF-1a.

In summary, i) routine quantitative DNA methylation assessment in NAF and MD samples is possible, and ii) genes hypermethylated in malignant breast tissue are also altered in matched NAF and in MD samples, and may be useful to assist in early breast cancer detection.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Cancer. 2003 Dec 20;107(6):970-5 [14601057.001]

[Cites] Kaohsiung J Med Sci. 2003 Sep;19(9):464-9 [14604322.001]

[Cites] Mod Pathol. 2003 Nov;16(11):1095-101 [14614048.001]

[Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):28-32 [14734448.001]

[Cites] Cancer J. 2004 Jan-Feb;10(1):33-41; discussion 15-6 [15000493.001]

[Cites] Cancer. 2004 Aug 25;102(4):259-68 [15368319.001]

[Cites] Cancer Res. 1977 Mar;37(3):646-50 [837366.001]

[Cites] Cancer Res. 1995 Nov 15;55(22):5195-9 [7585573.001]

[Cites] Science. 1996 Dec 20;274(5295):2057-9 [8953032.001]

[Cites] Am J Pathol. 1998 Jun;152(6):1591-8 [9626062.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891-6 [9751761.001]

[Cites] J Mol Med (Berl). 2005 Feb;83(2):132-9 [15536519.001]

[Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]

[Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3306-10 [16740751.001]

[Cites] Cancer Res. 2006 Aug 15;66(16):7899-909 [16912163.001]

[Cites] J Clin Oncol. 2006 Sep 10;24(26):4262-9 [16908936.001]

[Cites] Clin Cancer Res. 2006 Nov 15;12(22):6626-36 [17121881.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1812-21 [17855699.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1051-9 [18483325.001]

[Cites] Cancer Res. 2001 Feb 1;61(3):939-42 [11221887.001]

[Cites] Mol Cell Probes. 2000 Aug;14(4):211-7 [10970725.001]

[Cites] Onkologie. 2009 Mar;32(3):94-8 [19295246.001]

[Cites] Lancet. 2001 Apr 28;357(9265):1335-6 [11343741.001]

[Cites] Oncogene. 2001 Jun 7;20(26):3348-53 [11423985.001]

[Cites] Int J Oncol. 2001 Aug;19(2):277-81 [11445839.001]

[Cites] Cancer Res. 2002 Feb 15;62(4):1000-3 [11861372.001]

[Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]

[Cites] Am J Pathol. 2002 Jul;161(1):283-90 [12107113.001]

[Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]

[Cites] Br J Cancer. 1997;76(4):494-501 [9275027.001]

[Cites] Cancer Res. 1997 Oct 1;57(19):4158-61 [9331065.001]

[Cites] J Natl Cancer Inst. 1999 Feb 17;91(4):332-9 [10050866.001]

[Cites] Clin Cancer Res. 2005 Jan 1;11(1):166-72 [15671542.001]

(PMID = 19618401.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA124818-02; United States / NCI NIH HHS / CA / R21 CA124818; United States / NCI NIH HHS / CA / CA124818; United States / NCI NIH HHS / CA / R21 CA124818-02

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta

[Other-IDs] NLM/ NIHMS144203; NLM/ PMC3398695

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Epidemiology and morphology of breast benign tumors in Mali: about 186 cases].

[Transliterated title] Epidemiologie et morphologie des tumeurs benignes du sein au Mali: a propos de 186 cas.

Benign tumors are more frequent, and are characterized by a possibility of recurrence or malignant transformation.

The aim of this study was to describe the epidemiological and morphological characteristics of breast benign tumors.

The study had concerned all benign tumors confirmed by histology.

FINDINGS: In total, 186 benign tumors were diagnosed over 611 mammary pathologies (30.44%).

The main complaint was feeling a nodule in the breast (91.9%).

The most affected breast was the right side (50.8%).

Tumor sizes were variable, and the color changed through white to yellow.

Histological aspects were: fibroadenoma (72%), lipoma (8.6%), tubular adenoma (5.9%), papilloma (5.4%), lactating adenoma (3.8%), phyllodes tumor (3.8%), and syringomatous tumor (0.5%).

CONCLUSION: Benign tumors are frequent in mammary pathology.

[MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / pathology

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Mali / epidemiology. Middle Aged. Retrospective Studies. Young Adult

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19617151.001).

[ISSN] 1993-0836

[Journal-full-title] Le Mali médical

[ISO-abbreviation] Mali Med

[Language] fre

[Publication-type] English Abstract; Journal Article

[Publication-country] Mali

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression analysis and study of KLK4 in benign and malignant breast tumours.

The purpose of this study was the expression analysis and study of KLK4 in benign and malignant breast tumours.

Total RNA was isolated from 16 benign and 45 malignant breast tissue specimens.

Relative quantification analysis was performed using the comparative C(T) method 2(-DeltaDeltaC)(T) KLK4 expression was found to vary in both patients' cohorts; however, a statistically significant elevation of the KLK4 mRNA levels was observed in malignant compared to benign tumour patients.

ROC and logistic regression analysis recommended that KLK4 gene expression may be used as a new potential biomarker in breast cancer.

[MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Kallikreins / genetics

[MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Cell Line, Tumor. Female. Humans. Logistic Models. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Prognosis. RNA, Messenger / analysis. ROC Curve. Receptors, Progesterone / analysis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation. Young Adult

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19190825.001).

[ISSN] 0340-6245

[Journal-full-title] Thrombosis and haemostasis

[ISO-abbreviation] Thromb. Haemost.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Progesterone; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 4

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phyllodes tumor of the breast.

PURPOSE: To better identify prognostic factors for local control and survival, as well as the role of different therapeutic options, for phyllodes tumors, a rare fibroepithelial neoplasm of the breast.

Tumors were benign in 284 cases (64%), borderline in 80 cases (18%), and malignant in 79 cases (18%).

Surgery consisted of breast-conserving surgery (BCS) in 377 cases (85%) and total mastectomy (TM) in 66 cases (15%).

Multivariate analysis revealed benign histology, negative margins, and no residual disease (no RD) after initial treatment and RT delivery as independent favorable prognostic factors for local control; benign histology and low number of mitosis for disease-free survival; and pathologic tumor size < or = 3 cm and no tumor necrosis for overall survival.

CONCLUSIONS: This study showed that phyllodes tumor patients with no RD after treatment have better local control.

Benign tumors have a good prognosis after surgery alone.

[MeSH-major] Breast Neoplasms / surgery. Phyllodes Tumor / surgery

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Child. Female. Follow-Up Studies. Humans. Mastectomy. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Survival Rate

Genetic Alliance. consumer health - Phyllodes Tumor.

MedlinePlus Health Information. consumer health - Breast Cancer.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17931796.001).

[ISSN] 0360-3016

[Journal-full-title] International journal of radiation oncology, biology, physics

[ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.

[Language] eng

[Publication-type] Journal Article; Multicenter Study

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Benign breast biopsy diagnosis and subsequent risk of breast cancer.

BACKGROUND: We examine benign breast biopsy diagnoses as reported by community pathologists in New Mexico and investigate associations with future breast cancer development.

METHODS: Using data collected between 1992 and 2000 by the New Mexico Mammography Project and cancer data through 2003 from the New Mexico Tumor Registry, we calculated breast cancer rates following 14,602 benign breast biopsies for women ages 30 to 89 years.

For comparison, we also calculated the breast cancer rate following 215,283 normal screening mammograms.

RESULTS: We identified 480 subsequent breast cancer diagnoses among 14,602 women with benign breast biopsies and 4,402 breast cancer diagnoses among 215,283 women with mammograms assigned a "negative" or "benign finding" assessment.

Among low-risk histologic diagnoses, the strongest associations with subsequent breast cancer development included adenosis, apocrine metaplasia, calcifications, and ductal hyperplasia.

Fibroadenoma, inflammation, and cysts did not exhibit an association with breast cancer development.

Women with low-risk diagnoses and breast tissue characterized as fatty or with scattered densities had a HR of 2.09 (95% CI, 1.68-2.60), whereas women with low-risk histologic diagnoses and dense breasts had a HR of 3.36 (95% CI, 2.83-3.99).

CONCLUSIONS: The observed breast cancer occurrence contributes to evidence of increased risk following benign biopsy.

The risk associated with histologic diagnoses in absence of atypia was twice the risk experienced by women with normal mammogram evaluations and may be modified by breast density.

[MeSH-major] Breast Diseases / pathology. Breast Neoplasms / pathology. Risk

[MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Mammography. Middle Aged. New Mexico / epidemiology. Proportional Hazards Models. Registries

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Diseases.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17337650.001).

[ISSN] 1055-9965

[Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

[ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / 5 U01 CA69976

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk.

INTRODUCTION: The tumor suppressor genes RASSF1A, APC, H-cadherin, RARbeta2, and cyclin D2 are methylated more frequently in breast cancer than in adjacent benign tissue.

However, it is unclear whether promoter methylation of tumor suppressor genes in benign breast tissue is associated with an increased risk for breast cancer.

METHODS: Promoter hypermethylation was measured in benign and malignant breast samples obtained by fine needle aspiration biopsy from 27 breast cancer patients and 55 unaffected women whose risk of breast cancer had been defined using the Gail, Claus, and BRCAPRO models.

RESULTS: Cyclin D2 methylation occurred in 57% of tumor samples but not in corresponding benign breast samples and in only one sample from an unaffected patient (P < 0.0001).

RARbeta2 methylation occurred in 32% of benign breast samples from cancer patients but only 9% of similar samples from unaffected women (P = 0.002).

Promoter methylation of RASSF1A and APC occurred more frequently (70% and 56%, respectively) in unaffected women at high-risk for breast cancer as defined by the Gail model than in low/intermediate risk women (29% and 20%, P = 0.04 and P = 0.03).

Of the Gail model risk factors, only number of prior breast biopsies was highly correlated with APC and RASSF1A methylation (P = 0.0001 and 0.02, respectively).

CONCLUSIONS: Since cyclin D2 promoter methylation occurs almost exclusively in tumors, it may be possible to exploit it for the early detection of breast cancer.

Promoter methylation of APC, RARbeta2, and RASSF1A in benign breast epithelium is associated with epidemiologic markers of increased breast cancer risk.

[MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. DNA Methylation. Promoter Regions, Genetic

[MeSH-minor] Adult. Age Factors. Aged. Biopsy. Breast / pathology. Cadherins / biosynthesis. Cyclin D2. Cyclins / biosynthesis. Female. Humans. Middle Aged. Models, Theoretical. Polymerase Chain Reaction. Protein C / biosynthesis. Receptors, Retinoic Acid / biosynthesis. Risk. Tumor Suppressor Proteins / biosynthesis

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15671542.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA71618

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cadherins; 0 / Cyclin D2; 0 / Cyclins; 0 / H-cadherin; 0 / Protein C; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology.

In the present study, a two-dimensional liquid chromatography-tandem mass spectrometry (2D-LC-MS/MS) on a linear ion trap was utilized to identify and compare serum proteins from breast cancer patients.

Three groups of 21 human sera, 7 from patients with lymph node-negative invasive ductal carcinoma (IDCB), 7 from patients with lymph node-positive IDCB, and 7 controls from patients with benign breast diseases, were analyzed.

By quantification with label-free spectral counting, a fruitful list of serum proteins with significant differences in abundance accompanying the progression of breast cancer was found.

Among the selected proteins, tenascin-XB (TNXB) was further validated by the ELISA method in 131 serum samples as a promising biomarker for early metastasis of breast cancer.

[MeSH-major] Biomarkers, Tumor / metabolism. Breast Diseases / pathology. Breast Neoplasms / metabolism. Proteome / analysis. Proteomics / methods

[MeSH-minor] Adult. Case-Control Studies. Chromatography, Liquid / methods. Cluster Analysis. Computational Biology. Female. Humans. Lymphatic Metastasis. Middle Aged. Tandem Mass Spectrometry / methods

Genetic Alliance. consumer health - invasive ductal carcinoma.

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Diseases.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19624269.001).

[ISSN] 1557-8100

[Journal-full-title] Omics : a journal of integrative biology

[ISO-abbreviation] OMICS

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.

BACKGROUND: Gene-expression arrays have generated molecular predictors of relapse and drug sensitivity in breast cancer.

We aimed to identify exons differently expressed in malignant and benign breast lesions and to generate a molecular classifier for breast-cancer diagnosis.

METHODS: 165 breast samples were obtained by fine-needle aspiration.

A nearest centroid prediction rule was developed to classify lesions as malignant or benign on a training set, and its performance was assessed on an independent validation set.

A two-way ANOVA model identified probe sets with differential expression in malignant and benign lesions while adjusting for scan dates.

FINDINGS: 120 breast cancers and 45 benign lesions were included in the study.

A molecular classifier for breast-cancer diagnosis with 1228 probe sets was generated from the training set (n=94).

When the 165 samples were taken into account, 37 858 exon probe sets (5.4%) and 3733 genes (7.0%) were differently expressed in malignant and benign lesions (threshold: adjusted p<0.05).

In the same population of 165 samples, 956 exon probe sets presented both higher intensity and higher splice index in breast cancer than in benign lesions, although located on unchanged genes.

INTERPRETATION: Many exons are differently expressed by breast cancer and benign lesions, and alternative transcripts contribute to the molecular characteristics of breast malignancy.

Development of molecular classifiers for breast-cancer diagnosis with fine-needle aspiration should be possible.

[MeSH-major] Breast Neoplasms / genetics. Exons / genetics. Gene Expression Profiling. Neoplasms / genetics

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Carcinoma, Lobular / secondary. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA Splicing / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Validation Studies as Topic. Young Adult

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Lancet Oncol. 2009 Apr;10(4):314-5 [19341968.001]

(PMID = 19249242.001).

[ISSN] 1474-5488

[Journal-full-title] The Lancet. Oncology

[ISO-abbreviation] Lancet Oncol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Chromosomal aberrations and genetic relations in benign, borderline and malignant phyllodes tumors of the breast: a comparative genomic hybridization study.

Phyllodes tumors are not quite rare fibroepithelial neoplasms of the breast that show a broad spectrum of clinical behaviour.

We have used comparative genomic hybridization to analyze chromosomal copy number changes in 36 cases of phyllodes tumors (including benign, borderline and malignant phyllodes tumors, 12 cases each).

The average number of chromosome copy changes (range) in benign, borderline and malignant phyllodes tumors were 5.58 (0-20), 14.08 (3-23), and 12.42 (0-29) respectively.

In benign phyllodes tumors the number of gains and losses was in balance (2.50 vs 3.08), while in borderline and malignant phyllodes tumors gains occurred more often than losses (9.25 vs 4.83, 9.5 vs 2.92).

The result suggests the molecular cytogenetics of borderline and malignant phyllodes tumors is similar, and the most striking difference with benign phyllodes tumors is an increased number of chromosomal gains in a nonrandom distribution.

Gains of 4q12 seem especially to be involved in the progression of benign to borderline and malignant phyllodes tumors, possibly because of overexpression of oncogenes at these loci.

[MeSH-major] Breast Neoplasms / genetics. Chromosome Aberrations. Nucleic Acid Hybridization. Phyllodes Tumor / genetics

[MeSH-minor] Adult. Aged. Chromosome Mapping. Cytogenetic Analysis. Disease Progression. Female. Humans. Microdissection. Middle Aged. Models, Genetic. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18189161.001).

[ISSN] 1573-7217

[Journal-full-title] Breast cancer research and treatment

[ISO-abbreviation] Breast Cancer Res. Treat.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hormones and progeny of breast tumor cells.

The rudimentary human glandular breast, with the approach of puberty, starts to grow both at glandular and stromal sites.

The risk of breast cancer is inversely related to parity.

Women during adolescence have the highest susceptibility to breast cancer development.

Immunophenotypia of benign proliferative breast disease favors a fundamentally different epithelial composition from that of most malignant epithelial proliferations such as atypical ductal hyperplasia, ductal carcinoma in situ, lobular neoplasia and invasive breast carcinoma.

Immunophenotypical characterization of these lesions assists in distinguishing benign from malignant disease.

One should, however, realize that ductal as well as lobular premalignant breast lesions ultimately arise from stem cells in the terminal duct lobular units.

Based on our immunocytochemical observations, the most likely target cell of malignant transformation is the Ck18/18-positive and ER-negative transient cell of normal breast epithelium.

Pregnancy confers a different genomic imprint to breast epithelial stem cells.

Further elucidation of this mechanism may assist in developing appropriate means of breast cancer prevention.

[MeSH-major] Breast Neoplasms. Cell Transformation, Neoplastic. Mammary Glands, Human / cytology. Mammary Glands, Human / pathology. Neoplastic Stem Cells / pathology

[MeSH-minor] Cell Differentiation. Estrogens / physiology. Female. Genetic Predisposition to Disease. Humans. Immunohistochemistry. Parity. Pregnancy

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16698656.001).

[ISSN] 1369-7137

[Journal-full-title] Climacteric : the journal of the International Menopause Society

[ISO-abbreviation] Climacteric

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Estrogens

[Number-of-references] 63

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast.

PURPOSE: Our aim was to investigate the distribution of CD34 and smooth muscle cell actin positive myofibroblasts in the stroma of the normal mammary gland, benign and malignant tumors.

METHODS: Our study included 112 female patients with suspect breast masses obtained by surgery or biopsy.

RESULTS: We have found normal breast tissue, sclerosing adenosis, fibroadenomas, fibrocystic diseases, phyllodes tumor, DCIS, ductal invasive, lobular, squamous, medullary, mucinous, and papillary carcinomas.

All the normal breast tissues and most of benign lesions were positive for CD34 and negative for SMA.

The exceptions were represented by a case of fibroadenoma and the phyllodes tumor, with CD34 positivity and a focal acquisition of SMA; fibrocystic disease with associated apocrine metaplasia adjacent to a squamous carcinoma with loss of CD34 expression and focal acquisition of SMA.

CONCLUSIONS: Although there were some exceptions especially when one of the two markers was interpreted separately and in some cases associated with sclerotic stroma, we conclude that the combined expression of CD34 and a-SMA is of potential diagnostic value in the distinction between benign and malignant tumors in some difficult cases.

[MeSH-major] Actins / analysis. Antigens, CD34 / analysis. Breast Neoplasms / pathology. Muscle, Smooth / pathology

[MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Biopsy. Carcinoma, Ductal / pathology. Female. Fibrocystic Breast Disease / pathology. Humans. Middle Aged. Neoplasm Invasiveness. Smad Proteins / analysis

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16286998.001).

[ISSN] 1220-0522

[Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie

[ISO-abbreviation] Rom J Morphol Embryol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Romania

[Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Smad Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Biomonitoring of organochlorines in women with benign and malignant breast disease.

Established risk factors for breast cancer explain breast cancer risk only partially.

A hospital-based case-control study, the first from India, was conducted among 50 women undergoing surgery for breast disease to examine the association between organochlorine exposure and breast cancer risk.

Blood, tumor, and surrounding adipose tissue of the breast were collected from the subjects with benign (control) and malignant breast (study) lesions and analyzed to determine organochlorine insecticides using a gas-liquid chromatograph equipped with an electron capture detector.

However, both total HCH and total DDT were higher in the tumor tissues of the controls than in those of the study group; gamma-HCH was significantly different (P<0.05).

The level of total HCH (alpha-HCH was significantly different, P<0.05) was higher in the breast adipose tissue of the study group, whereas total DDT was higher in the breast adipose tissue of the control group.

The distribution of known confounders of breast cancer including age, body mass index, age at menarche and menopause, duration of breast feeding, and family history related to breast disease did not differ significantly between benign and malignant groups.

This pilot study with limited statistical power does not support a positive association between exposure to organochlorines and risk of breast cancer but paves the way for a larger Indian study with greater statistical power encompassing different regions of the country to enable statistically sound conclusions.

[MeSH-major] Breast Neoplasms / etiology. Environmental Monitoring. Environmental Pollutants / pharmacokinetics. Hydrocarbons, Chlorinated / pharmacokinetics

[MeSH-minor] Adipose Tissue / metabolism. Adult. Age Factors. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Case-Control Studies. Chromatography, Gas. Female. Humans. Mammography. Middle Aged. Pilot Projects. Risk Factors. Tissue Distribution

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15820732.001).

[ISSN] 0013-9351

[Journal-full-title] Environmental research

[ISO-abbreviation] Environ. Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Environmental Pollutants; 0 / Hydrocarbons, Chlorinated

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Detection of free tumor-related DNA in the serum of breast cancer patients].

OBJECTIVE: To study the APC and E-cadherin gene promoter hypermethylation as tumor marker and to investigate the correlation of free tumor-related DNA in serum and tumor tissue with clinicopathological parameters.

Their feasibility in early diagnosis, predicting therapeutic effect and monitoring recurrence was evaluated.

METHODS: 84 cases with operated breast cancer were recruited from March 2002 to August 2002 at Beijing Cancer Hospital.

Aberrant methylation of E-cadherin and APC genes was detected in tumor tissues, adjacent normal tissues and peripheral blood serum by methylation-specific PCR (MSP).

10 cases with benign breast diseases were selected as control group.

RESULTS: The positive rate of promoter hypermethylation of E-cadherin and APC genes in tumor tissues was 52.4% and 45.2%, in the paired serum was 33.3% and 31.0%, respectively.

Aberrant methylation of free DNA in serum presented the same alteration in tumor tissues.

E-cadherin and APC hypermethylation in serum and tumor samples significantly correlated each other (E-cadherin P < 0.001; APC P = 0.002).

There was no correlation for the aberrant methylation in cancer tissues and serum with the clinicopathological parameters of patients including age, tumor staging, tumor size, histological type and receptor.

CONCLUSION: The same aberrant methylation in cancer tissues and serum, not correlating with tumor staging, can be detected in about one third of breast cancer patients.

The results imply that this approach may be feasible for early diagnosis, evaluation of therapeutic effects and monitoring recurrence of breast cancers.

[MeSH-major] Breast Neoplasms / genetics. Cadherins / genetics. DNA Methylation. DNA, Neoplasm / blood. Genes, APC. Genes, Tumor Suppressor

[MeSH-minor] Adult. Aged. Biomarkers, Tumor. CpG Islands. Female. Humans. Middle Aged. Promoter Regions, Genetic. Sensitivity and Specificity. Young Adult

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18210882.001).

[ISSN] 0253-3766

[Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]

[ISO-abbreviation] Zhonghua Zhong Liu Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / DNA, Neoplasm

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories.

Matrix metalloproteinase (MMP) 2 and 9 are involved in cancer invasion and metastasis, and increased levels occur in serum and plasma of breast cancer (BC) patients.

In our study, we measured concentration and activity of MMP2/9 in sera of 345 donors classified as low risk (Gail score <1.7), high risk (HR) (Gail score > or =1.7), benign disease or BC.

Kruskal-Wallis and Mann-Whitney nonparametric tests showed that total-MMP2 concentration is higher in HR compared to control (p = 0.012), benign (p = 0.001) and cancer (p = 0.007).

Active MMP2 (aMMP2) concentration is higher in control than benign and cancer (p < 0.001, respectively).

Total and aMMP9 concentrations are higher in cancer than benign (p < 0.001, p = 0.002, respectively).

Total-MMP2 and total-MMP9 activities are lower in control than benign (p < 0.001, p = 0.002, respectively) and cancer (p < 0.001, respectively).

Total-MMP2 and MMP9 activities are also higher in cancer than benign (p = 0.004, p < 0.001) and HR (p = 0.008, p = 0.007, respectively).

Our study provides evidence supporting the potential role of serum MMP2/9 as biomarkers for breast disease classification.

[MeSH-major] Breast Diseases / enzymology. Breast Neoplasms / enzymology. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood

[MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Breast / enzymology. Carcinoma, Intraductal, Noninfiltrating / enzymology. Female. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Prognosis. Risk Factors

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Diseases.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Int J Cancer. 2007 Jul 1;121(1):216-8; author reply 219-23 [17315186.001]

(PMID = 16615109.001).

[ISSN] 0020-7136

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Ki-67 expression in benign breast ductal cells obtained by random periareolar fine needle aspiration.

Ki-67 expression in ductal cells obtained by random periareolar fine needle aspiration (RPFNA) is currently being used as a response biomarker in phase II breast cancer chemoprevention trials; however, Ki-67 in RPFNA has not been well studied as a risk predictor for cancer, which would support its use as a response indicator.

We examined the expression of Ki-67 in RPFNA specimens with hyperplasia +/- atypia obtained from 147 women at high risk for development of breast cancer.

The association of Ki-67 expression with cytologic atypia, a known risk factor for development of breast cancer, provides preliminary justification for its use as a response biomarker in phase II chemoprevention trials.

[MeSH-major] Biomarkers, Tumor / isolation & purification. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Ki-67 Antigen / isolation & purification

[MeSH-minor] Adult. Aged. Cohort Studies. Female. Hormone Replacement Therapy. Humans. Hyperplasia. Menopause. Middle Aged. Postmenopause

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15824144.001).

[ISSN] 1055-9965

[Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

[ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.

[Language] eng

[Grant] United States / NCI NIH HHS / CN / N01-CN-15135

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease.

Changes in the levels of malondialdehyde (MDA), nitrate and nitrite (as an index of nitric oxide production), lipid hydroperoxide (LOH), total antioxidant capacity (TAC), lipids (total cholesterol and triglycerides) and lipoproteins (HDL- and LDL-cholesterol) were estimated in breast cancer patients (n = 15) and benign breast disease (n = 15).

Serum and tissue MDA levels were found to be decreased in breast cancer patients compared to the benign group (p < 0.05).

In contrast, nitrate and nitrite levels were increased in serum and tissue of the cancer group compared to benign breast disease patients (p < 0.05).

Compared to the benign group, tissue TAC levels were elevated in the breast cancer patient group (p < 0.05).

Total cholesterol and HDL-cholesterol were elevated in the benign group compared with cancer patients (p < 0.05).

These findings support the hypothesis that lipid peroxidation in serum and tissue of benign breast disease is greater than in breast cancer.

However, the enhanced levels of nitric oxide may be in response to inflammation in patients with breast cancer.

Total antioxidant status is lower in benign tissue than in cancerous tissue, probably to compensate for this elevated free radical production.

[MeSH-major] Antioxidants / metabolism. Breast / metabolism. Breast / pathology. Breast Neoplasms / blood. Breast Neoplasms / metabolism. Lipid Peroxidation

[MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lipid Peroxides / blood. Malondialdehyde / blood. Middle Aged. Nitrates / blood. Nitrites / blood

MedlinePlus Health Information. consumer health - Antioxidants.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16616293.001).

[ISSN] 1065-6995

[Journal-full-title] Cell biology international

[ISO-abbreviation] Cell Biol. Int.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antioxidants; 0 / Lipid Peroxides; 0 / Nitrates; 0 / Nitrites; 4Y8F71G49Q / Malondialdehyde

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Benign breast lesions that simulate malignancy: magnetic resonance imaging with radiologic-pathologic correlation.

The typical appearance of benign breast conditions on magnetic resonance imaging (MRI) is well established and diagnosis is usually easy.

However, cases of benign breast lesions that are extremely difficult to differentiate from malignant breast tumors are occasionally encountered in MRI of the breast because overlap between benign and malignant lesions characteristics is found.

This article describes the MRI features of a variety of suspicious breast conditions that were confirmed to be benign in the histopathologic study.

We evaluated both enhancement kinetics and lesion morphological information to differentiate malignant from benign lesions.

Lesions evaluated included benign proliferative breast disease, fibroadenoma, intraductal papilloma, granular cell tumor, pseudoangiomatous stromal hyperplasia, fat necrosis, mastitis, inflammatory granuloma, epidermal inclusion cyst, and benign intramammary lymph node.

[MeSH-major] Breast Diseases / diagnosis. Magnetic Resonance Imaging

[MeSH-minor] Breast Cyst / diagnosis. Breast Neoplasms / diagnosis. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Granular Cell Tumor / diagnosis. Humans. Mastitis / diagnosis. Papilloma / diagnosis

MedlinePlus Health Information. consumer health - Breast Diseases.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17331838.001).

[ISSN] 0363-0188

[Journal-full-title] Current problems in diagnostic radiology

[ISO-abbreviation] Curr Probl Diagn Radiol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hepatocyte growth factor in Egyptian females with breast benign lumps and cancers.

BACKGROUND: Hepatocyte growth factor (HGF) also known as scatter factor (SF) and its receptor c-met play important roles in mammary differentiation and have been implicated in mammary carcinogenesis.

OBJECTIVE: Estimation of the plasma level of HGF in females with benign breast lumps or breast carcinomas and correlating levels with important prognostic parameters.

SUBJECTS: Sixty eight adult premenopausal females were divided into control group of fifteen healthy volunteers and fifty-three patients subdivided into fifteen with benign breast lumps and thirty-eight with breast carcinomas.

METHODS: A thorough clinical examination, plain chest x-rays, ultrasonography of the abdomen and pelvis, pre- operative fine needle aspiration cytology, estimation of fasting serum glucose, urea, creatinine and uric acid levels, alanine aminotransferase activities, C-reactive protein, HGF level and histopathological examination of the breast masses were performed.

RESULTS: Significant increase in HGF levels was found in patients with benign breast lumps and in breast cancer patients when each was compared to controls and when cancer patients were compared to the benign breast lumps group.

CONCLUSION: The serum level of HGF is an independent prognostic indicator for breast cancer.

[MeSH-major] Breast Neoplasms / blood. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / blood. Carcinoma, Ductal, Breast / pathology. Fibroadenoma / blood. Hepatocyte Growth Factor / blood

[MeSH-minor] Age Factors. Egypt. Female. Fibrocystic Breast Disease / blood. Humans. Inflammation / blood. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Burden

MedlinePlus Health Information. consumer health - Breast Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21133597.001).

[ISSN] 2476-762X

[Journal-full-title] Asian Pacific journal of cancer prevention : APJCP

[ISO-abbreviation] Asian Pac. J. Cancer Prev.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Thailand

[Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 67256-21-7 / Hepatocyte Growth Factor

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Ultrasonographic features of benign adenomyoepithelioma of the breast.

OBJECTIVE: The purpose of this study was to evaluate the ultrasonographic features of benign adenomyoepithelioma of the breast.

MATERIALS AND METHODS: Between 2005 and 2009, five patients had histologically confirmed adenomyoepithelioma of the breast.

The ultrasonographic assessments were classified as Breast Imaging Reporting and Data System (BI-RADS) category 4A, with low suspicion of malignancy in two cases, and as category 4B, with intermediate suspicion of malignancy in three cases.

The pathology revealed benign adenomyoepithelioma in all patients.

CONCLUSION: Benign adenomyoepitheliomas appear as solid or complex echoic masses with suspicious malignant ultrasonographic features, which may be associated with adjacent ductectasia.

Although adenomyoepithelioma is a rare breast tumor, awareness of its sonographic features will be helpful for the differential diagnosis from other tumors.

[MeSH-major] Adenomyoepithelioma / ultrasonography. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary

[MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Mammography. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Arch Pathol Lab Med. 2000 Apr;124(4):632-6 [10747327.001]

[Cites] Acta Cytol. 2000 May-Jun;44(3):488-90 [10834021.001]

[Cites] J Ultrasound Med. 2001 Sep;20(9):1021-4 [11549151.001]

[Cites] Breast J. 2002 Nov-Dec;8(6):383-4 [12390363.001]

[Cites] AJR Am J Roentgenol. 2003 Mar;180(3):799-803 [12591699.001]

[Cites] Breast. 2004 Aug;13(4):356-8 [15325675.001]

[Cites] Breast Cancer. 2007;14(4):429-33 [17986811.001]

[Cites] Hum Pathol. 1987 Dec;18(12):1232-7 [2824328.001]

[Cites] Am J Surg Pathol. 1991 Jun;15(6):554-68 [1709559.001]

[Cites] Am J Surg Pathol. 1992 Sep;16(9):868-76 [1384377.001]

[Cites] Breast J. 2006 Jul-Aug;12(4):386 [16848857.001]

[Cites] Breast J. 2007 Mar-Apr;13(2):203-4 [17319866.001]

[Cites] Acta Radiol. 2007 Feb;48(1):27-9 [17325921.001]

[Cites] Curr Top Pathol. 1970;53:161-220 [4323195.001]

(PMID = 20808695.001).

[ISSN] 2005-8330

[Journal-full-title] Korean journal of radiology

[ISO-abbreviation] Korean J Radiol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Korea (South)

[Other-IDs] NLM/ PMC2930160

[Keywords] NOTNLM ; Adenomyoepithelioma / Breast / Ultrasonography

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma.

One hypothesis for breast cancer development suggests that breast carcinogenesis involves a progression of events leading from benign epithelium to hyperplasia (with or without atypia) to carcinoma in situ and then invasive carcinoma.

Benign lesions and normal adjacent cells were classified as normal.

The presence of MYC amplification only in invasive cells suggests that the finding of MYC amplification could reflect an advanced tumor progression.

[MeSH-major] Breast Neoplasms / genetics. Genes, myc

[MeSH-minor] Chromosomes, Human, Pair 8. Disease Progression. Female. Humans. In Situ Hybridization, Fluorescence. Neoplasm Invasiveness. Paraffin Embedding

Genetic Alliance. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16527609.001).

[ISSN] 0165-4608

[Journal-full-title] Cancer genetics and cytogenetics

[ISO-abbreviation] Cancer Genet. Cytogenet.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells.

There is increased staining of endothelins (ET-1, -2, and -3) and receptors (ET-RA and -RB) in invasive breast tumors compared to nonneoplastic tissue, and ETs stimulate MCF-7 cell invasion in vitro.

We analyzed ETstimulation of benign and transformed mammary epithelial cells, and whether expression of ETs is sufficient to induce invasiveness.

In breast cancer patient serum, ET-1 was increased in those patients with lymph node metastases compared to those with no lymph node involvement; ETs, however, had no mitogenic effect on breast tumor cell lines in vitro.

The benign mammary epithelial cell line, hTERT-HME1, and the poorly invasive breast tumor cell line MCF-7 secreted low levels of ET-1, while the invasive cell lines SKBR3 and MDAMB231 secreted high levels.

In contrast to transformed cells, ET stimulation or overexpression did not induce an invasive phenotype in benign cells.

Benign cells do not respond to ETs, and ET expression is not sufficient to induce invasion; however, the level of ET production by tumor cells correlates with their invasiveness, and increasing expression of the ET axis promotes breast tumor cell invasion via both receptors, while MMP-14 is induced via ET-RA.

[MeSH-major] Breast Neoplasms / metabolism. Endothelins / biosynthesis. Epithelial Cells / metabolism. Receptor, Endothelin A / biosynthesis. Receptor, Endothelin B / biosynthesis

[MeSH-minor] Calcium / metabolism. Cell Line. Cell Line, Tumor. Endothelin-1 / blood. Endothelin-1 / metabolism. Enzyme Induction. Female. Humans. Lymphatic Metastasis. Mammary Glands, Human / metabolism. Mammary Glands, Human / pathology. Matrix Metalloproteinases / biosynthesis. Neoplasm Invasiveness. Phenotype. Signal Transduction

MedlinePlus Health Information. consumer health - Breast Cancer.

Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16274297.001).

[ISSN] 1044-5498

[Journal-full-title] DNA and cell biology

[ISO-abbreviation] DNA Cell Biol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Endothelin-1; 0 / Endothelins; 0 / Receptor, Endothelin A; 0 / Receptor, Endothelin B; EC 3.4.24.- / Matrix Metalloproteinases; SY7Q814VUP / Calcium

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Rare benign breast tumor.

We report the case of a female patient with an incidental finding at routine mammography evaluation which consisted of a benign spindle cell tumor, namely Breast Myofibroblastoma.

It is important to recognize the benign nature of this neoplasm to prevent extensive mutilating surgical procedures.

[MeSH-major] Breast Neoplasms / pathology. Neoplasms, Muscle Tissue / pathology

[MeSH-minor] Female. Humans. Middle Aged

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20939206.001).

[ISSN] 0004-4849

[Journal-full-title] Boletín de la Asociación Médica de Puerto Rico

[ISO-abbreviation] Bol Asoc Med P R

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Puerto Rico

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immune system modulation in patients with malignant and benign breast disorders: tryptophan degradation and serum neopterin.

Tryptophan degradation metabolites are known to suppress T-cell function, which is a mechanism of resistance of tumor cells against immune surveillance.

The aim of this study was to evaluate tryptophan degradation along with serum neopterin levels in benign and malignant breast disease.

Serum tryptophan and kynurenine levels and neopterin concentrations of 30 patients with malignant and 27 patients with benign breast disease were determined by HPLC and ELISA, respectively.

Neopterin levels in patients with malignant breast disease were significantly higher than in the benign group (p<0.05).

Tryptophan degradation positively correlates with the aggressiveness of the tumor because it changes with tumor grade rather than disease stage.

[MeSH-major] Breast Neoplasms / immunology. Neopterin / blood. Tryptophan / metabolism

[MeSH-minor] Adult. Female. Humans. Indoleamine-Pyrrole 2,3,-Dioxygenase / physiology. Kynurenine / blood. Middle Aged

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20082276.001).

[ISSN] 0393-6155

[Journal-full-title] The International journal of biological markers

[ISO-abbreviation] Int. J. Biol. Markers

[Language] eng

[Publication-type] Journal Article

[Publication-country] Italy

[Chemical-registry-number] 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase; 343-65-7 / Kynurenine; 670-65-5 / Neopterin; 8DUH1N11BX / Tryptophan

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Late-fluorescence mammography assesses tumor capillary permeability and differentiates malignant from benign lesions.

Using scanning time-domain instrumentation we recorded fluorescence projection mammograms on few breast cancer patients prior, during and after infusion of indocyanine green (ICG), while monitoring arterial ICG concentration by transcutaneous pulse densitometry.

Late-fluorescence mammograms recorded after ICG had been largely cleared from the blood by the liver, showed invasive carcinomas at high contrast over a rather homogeneous background, whereas benign lesions did not produce (focused) fluorescence contrast.

During infusion, tissue concentration contrast and hence fluorescence contrast is determined by intravascular contributions, whereas late-fluorescence mammograms are dominated by contributions from protein-bound ICG extravasated into the interstitium, reflecting relative microvascular permeabilities of carcinomas and normal breast tissue.

[MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / diagnosis. Capillary Permeability / physiology. Mammography / methods

[MeSH-minor] Adult. Aged. Aged, 80 and over. Computer Simulation. Diagnosis, Differential. Female. Fluorescence. Humans. Indocyanine Green / metabolism. Middle Aged. Time Factors

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Mammography.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19770920.001).

[ISSN] 1094-4087

[Journal-full-title] Optics express

[ISO-abbreviation] Opt Express

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] IX6J1063HV / Indocyanine Green

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Serum biomarkers to differentiate benign and malignant mammographic lesions.

BACKGROUND: Mammographic screening has increased detection of earlier-stage breast cancers and has decreased mortality from breast cancer.

A Breast Imaging-Reporting and Data System (BIRADS) 4 classification prompts a biopsy that most often reveals benign disease.

Our objective was to determine if serum protein-expression profiles could be used to differentiate between benign and malignant mammographic lesions.

Sera from 92 subjects were randomly selected to form benign (n = 46) and cancer (n = 46) cohorts.

The MALDI-TOF spectra analysis yielded 273 peaks, with 14 peaks expressed differentially (p < 0.05) between the cancer and benign cohorts.

CONCLUSIONS: MALDI-TOF protein-expression profiles generated from BIRADS 4 sera could be used to distinguish between benign and malignant mammographic lesions.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17481542.001).

[ISSN] 1072-7515

[Journal-full-title] Journal of the American College of Surgeons

[ISO-abbreviation] J. Am. Coll. Surg.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U01 CA085067; United States / NCI NIH HHS / CA / U01 CA98028

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Dual-modality breast tomosynthesis.

PURPOSE: To evaluate the clinical performance of a hybrid scanner that uses dual-modality tomosynthesis (DMT) and technetium 99m sestamibi to provide coregistered anatomic and functional breast images in three dimensions.

MATERIALS AND METHODS: A prospective pilot evaluation of the scanner was performed in women scheduled to undergo breast biopsy after institutional review board approval and informed consent were obtained.

RESULTS: Of the 21 lesions, seven were malignant, and 14 were benign.

CONCLUSION: Pilot clinical evaluation of the DMT scanner suggests that it is a feasible and accurate method with which to detect and diagnose breast cancer.

Systems such as the DMT scanner that are designed specifically for three-dimensional multimodality breast imaging could make possible some of the advances in tumor detection, localization, and characterization of breast cancer that are now being observed with whole-body three-dimensional hybrid systems, such as positron emission tomography/computed tomography (CT) or single photon emission computed tomography/CT.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] RSNA, 2010

[Cites] Med Phys. 1999 Nov;26(11):2273-85 [10587208.001]

[Cites] Breast J. 2007 Sep-Oct;13(5):465-9 [17760667.001]

[Cites] J Nucl Med. 2001 Jan;42(1):3-8 [11197976.001]

[Cites] Ann Intern Med. 2002 Sep 3;137(5 Part 1):347-60 [12204020.001]

[Cites] Ann Intern Med. 2003 Feb 4;138(3):168-75 [12558355.001]

[Cites] Technol Cancer Res Treat. 2002 Feb;1(1):39-42 [12614175.001]

[Cites] AJR Am J Roentgenol. 2003 Jun;180(6):1675-9 [12760942.001]

[Cites] Phys Med Biol. 2003 Oct 7;48(19):R65-106 [14579853.001]

[Cites] Anticancer Res. 1997 May-Jun;17(3B):1631-4 [9179208.001]

[Cites] J Nucl Med. 1998 Mar;39(3):449-53 [9529290.001]

[Cites] Eur J Nucl Med. 1998 Apr;25(4):375-85 [9553167.001]

[Cites] Acad Radiol. 2005 Mar;12(3):286-90 [15766687.001]

[Cites] Technol Cancer Res Treat. 2005 Jun;4(3):265-73 [15896082.001]

[Cites] Radiology. 2005 Oct;237(1):274-80 [16126919.001]

[Cites] Int J Cancer. 2006 Jul 15;119(2):414-22 [16646006.001]

[Cites] Conf Proc IEEE Eng Med Biol Soc. 2007;2007:1335-8 [18002210.001]

[Cites] J Natl Cancer Inst. 2008 Jun 18;100(12):876-87 [18544742.001]

[Cites] Med Phys. 2008 Jun;35(6):2414-23 [18649474.001]

[Cites] Am J Surg. 2008 Oct;196(4):470-6 [18723155.001]

[Cites] AJR Am J Roentgenol. 2008 Dec;191(6):1805-15 [19020253.001]

[Cites] AJR Am J Roentgenol. 2009 Feb;192(2):379-83 [19155397.001]

[Cites] Am J Surg. 2009 Feb;197(2):159-63 [19185109.001]

[Cites] Radiology. 2009 Jun;251(3):673-82 [19474373.001]

[Cites] J Nucl Med. 2009 Sep;50(9):1401-8 [19690029.001]

[Cites] Phys Med Biol. 2006 Oct 7;51(19):5051-64 [16985287.001]

[Cites] Neuroimaging Clin N Am. 2006 Nov;16(4):575-89, viii [17148020.001]

[Cites] Phys Med Biol. 2007 Feb 7;52(3):603-16 [17228108.001]

[Cites] Oncology. 2006;70(6):403-10 [17237619.001]

[Cites] J BUON. 2006 Jan-Mar;11(1):61-8 [17318954.001]

[Cites] Acad Radiol. 2007 Aug;14(8):945-50 [17659240.001]

[Cites] Q J Nucl Med. 2000 Jun;44(2):168-85 [10967626.001]

(PMID = 20308457.001).

[ISSN] 1527-1315

[Journal-full-title] Radiology

[ISO-abbreviation] Radiology

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA069452; United States / NCI NIH HHS / CA / R01 CA 69452

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi

[Other-IDs] NLM/ PMC2843832